Concomitant Medications\r\n* Corticosteroids: patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n** Note: hydrocortisone used as a pre-medication to prevent transfusion related reactions is not considered a concomitant corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible (except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)\r\n* Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial\r\n* Cardiac medications: any medications for treatment of left ventricular systolic dysfunctionXx_NEWLINE_xXWOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXNot currently receiving anticoagulation therapyXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXAnti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients receiving treatment with St. John's wort or Phenytoin.Xx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid \r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are receiving any investigational agent other than pevonedistat, including but not limited to androgens, supraphysiologic doses of corticosteroids, erythropoietin, eltrombopag, or romiplostimXx_NEWLINE_xXIf a patient is currently receiving denosumab, this must be discontinued prior to enrollment. Substitution with biphosphonates are acceptable.Xx_NEWLINE_xXOther non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-upXx_NEWLINE_xXOther non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-upXx_NEWLINE_xXPatients may not be receiving Coumadin while on treatment; other anticoagulants are allowedXx_NEWLINE_xXSR1 and SR2 patients:Xx_NEWLINE_xXPatients must not be registered to step 2 until receiving confirmation from the Southwest Oncology Group (SWOG) Statistical Center that the patient's tissue specimen was adequate for PD-L1 testing; patients must be registered within 7 days of receiving the e-mail notification confirming submission was evaluable for PD-L1 statusXx_NEWLINE_xXPatients must not currently be receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior); all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4Xx_NEWLINE_xXPatients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapyXx_NEWLINE_xXPatients must not be receiving any proton pump inhibitors at the time of registrationXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are receiving drugs that prolong QTc are not eligibleXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A/CYP3A4 agents: patients who are currently receiving drugs that are strong and moderate inducers or inhibitors of CYP3A or CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 21 days prior to enrollment to the end of the studyXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYP2C9 agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYP2C9 are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are currently receiving drugs that are inhibitors or inducers of p-glycoprotein (P-gp) or adenosine triphosphate (ATP)-binding cassette, subfamily G, member 2 (ABCG2 [BCRP]) are not eligibleXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n** Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowedXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trialXx_NEWLINE_xXPatients who are currently receiving another investigational drugXx_NEWLINE_xXSubjects receiving any investigational drug concurrently.Xx_NEWLINE_xXPatients currently taking metformin will be eligibleXx_NEWLINE_xXPatients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatmentXx_NEWLINE_xXPatients receiving live/attenuated vaccinations within 4 weeks prior to registration are not eligibleXx_NEWLINE_xXSubjects receiving any investigational drug concurrently.Xx_NEWLINE_xX-  INCLUSION CRITERIA:\n\n          -  Patients of any age or either gender with indications for receipt of investigational\n             HPC-CORD BLOOD who are participating in an NIH-IRB approved clinical trial for\n             unrelated hematopoietic stem cell transplantation.\n\n          -  Signed informed consent (and assent when applicable).\n\n        EXCLUSION CRITERIA:\n\n          -  Patients who are receiving licensed CB products (only)\n\n          -  Patients who are receiving unlicensed CB products from other CB banks (i.e. NMDP)Xx_NEWLINE_xXThe eligibility of patients receiving any medications or substances known or with potential to affect the activity or pharmacokinetics of temozolomide and/or pazopanib will be determined following review of the case by the Principal Investigator; efforts should be made to switch patients who are taking enzyme-inducing agents to other medicationsXx_NEWLINE_xXPatients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollmentXx_NEWLINE_xXPatients who are receiving any other anticancer or investigational or/and anti-neoplastic therapies, including chemotherapy, immunotherapy, target therapy, biological response modifiers\r\n* Previous treatment with CDK4/6 inhibitors (such as PD-0332991, abemaciclib) and/or mTOR inhibitors (such as sirolimus, temsirolimus or everolimus)\r\n* Patients who are currently receiving treatment with agents that are known to cause corrected QT (QTc) prolongation or induce Torsades de Pointes\r\n* Known need for major surgery within 14 days of the first dose of ribociclib and everolimus; please note: gastrostomy, insertion of a gastrostomy (G) tube, ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access are NOT considered major surgeryXx_NEWLINE_xXCurrently taking 3 or more anti-hypertensive medicationsXx_NEWLINE_xXPrior history of receiving pazopanib treatmentsXx_NEWLINE_xXHas receiving immunosuppressive or other contraindicated therapies within the excluded time frame from entryXx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXFor Groups B or C patients must be off conventional therapy for at least 1 week prior to receiving treatment on this studyXx_NEWLINE_xXPatients may have received other vascular endothelial growth factor (VEGF) blocking tyrosine kinase inhibitors, provided that they did not progress while receiving one of these agents; patients may not have previously received pazopanib; patients must have recovered from any VEGF blocking drug-related toxicity (e.g., proteinuria); patients previously treated with irinotecan and/or temozolomide will be eligible for this study provided they did not progress while receiving one of these agentsXx_NEWLINE_xXPatients with a known history of seizures must have well-controlled seizures and may not be receiving enzyme-inducing anti-convulsantsXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents or radiation therapy are not eligibleXx_NEWLINE_xXPatients who are currently receiving more than one anti-hypertensive medication (grade 3) or whose blood pressure is not controlled are not eligible for study enrollmentXx_NEWLINE_xXPatients currently receiving aspirin, and/or ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs) are not eligibleXx_NEWLINE_xXPatients who are currently receiving enzyme-inducing anti-convulsants are not eligibleXx_NEWLINE_xXPatients receiving drugs with a known risk of torsades de pointes are not eligible; Note: This list includes the prohibition of grapefruit for 14 days prior to enrollmentXx_NEWLINE_xXPatients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapyXx_NEWLINE_xXPatients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).Xx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.Xx_NEWLINE_xXPatients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on study.Xx_NEWLINE_xXCurrently taking disease modifying rheumatoid drugs (DMRDs)Xx_NEWLINE_xXPatients currently receiving investigational or commercial anti-cancer agents or anti-cancer therapies other than BCG, ALT-803 and supportive care therapies.Xx_NEWLINE_xXCurrently taking a prohibited concomitant medication, other than a premedication, that are/is:Xx_NEWLINE_xXPatients receiving systemic treatment with any immunosuppressive medication, excepting the aboveXx_NEWLINE_xXPatients must be either:Xx_NEWLINE_xXCurrently receiving experimental treatment with non-approved drugs at the time of enrolment. Patients must undergo a 28-day washout between last dose and screening CPET.Xx_NEWLINE_xXSubjects who are currently receiving enzyme inducing anticonvulsants are not eligibleXx_NEWLINE_xXSubjects who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXSubjects who are currently receiving any other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are unwilling to stop the use of herbal remedies while receiving study treatmentXx_NEWLINE_xXPatients must:Xx_NEWLINE_xXSubjects may not be receiving any chemotherapy or other agents intended for oncologic treatmentXx_NEWLINE_xXPatients with other fibroblastic lesions or other fibromatoses are NOT eligible.Xx_NEWLINE_xXHistory of receiving any investigational treatment or other systemic therapy directed at controlling cancer (e.g., chemotherapy, trastuzumab, etc.) since the participant's last study drug dose in the parent studyXx_NEWLINE_xXAny known factors that would pose a contraindication to receiving nivolumabXx_NEWLINE_xXPatients currently receiving and unable to stop high doses of supplemental vitamin EXx_NEWLINE_xXPT/INR ? ULN within 28 days of randomization. Patients receiving therapeutic anti-coagulants are not eligible.Xx_NEWLINE_xXPatients receiving hemodialysis or peritoneal dialysisXx_NEWLINE_xXINR ? 1.6 (unless receiving anticoagulation therapy).Xx_NEWLINE_xXParticipant that received in the 7 days prior to the administration of study drug or is currently receiving any of the following medications:Xx_NEWLINE_xXSubjects receiving anticoagulation therapyXx_NEWLINE_xXPatients currently receiving active treatment for melanomaXx_NEWLINE_xXPatients should have been off conventional therapy for at least 1 week prior to receiving treatment on this studyXx_NEWLINE_xXEXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeksXx_NEWLINE_xXSubjects receiving prednisone or steroids must continue on the same dose they were receiving at the time of screeningXx_NEWLINE_xXPatients currently receiving other anti-melanoma treatment; toxicities attributable to any prior therapy must have resolved to grade 1 or better prior to enrollmentXx_NEWLINE_xXPatients receiving steroid treatment exceeding replacement dosingXx_NEWLINE_xXCurrently receiving exogenous estrogen replacement therapy (topical vaginal estrogen therapy is allowed)Xx_NEWLINE_xXPatients must be receiving optimal therapy for their extracranial disease according to local practice at each center. Patients may continue on systemic therapy while receiving TTFields.Xx_NEWLINE_xXOther non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-upXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligible.Xx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.Xx_NEWLINE_xXPatients who are currently receiving more than one anti-hypertensive medication (Grade 3) or whose blood pressure is not well controlled are not eligible for study enrollment.Xx_NEWLINE_xXPatients receiving drugs with a known risk of torsades de pointes are not eligible.Xx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)Xx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are chronically receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs are not eligibleXx_NEWLINE_xXPatients who are currently receiving anti-platelet agents are not eligibleXx_NEWLINE_xXPatients who are receiving anti-hypertensive medications for control of blood pressure at the time of enrollment are not eligible for this trialXx_NEWLINE_xXPatients who are currently receiving belimumab (a monoclonal antibody for systemic lupus erythematosus) are not eligibleXx_NEWLINE_xXPatients who are currently receiving bisphosphonate derivatives are not eligibleXx_NEWLINE_xXPatients receiving corticosteroids are eligible for this trialXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients must not currently be receiving enzyme inducing anticonvulsantsXx_NEWLINE_xXPatients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are availableXx_NEWLINE_xXPatients receiving concomitant medication that may interfere with study outcome; for example, patients cannot be on enzyme inducing anticonvulsants like phenytoinXx_NEWLINE_xXCorticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registrationXx_NEWLINE_xXPatients receiving anticoagulation therapy with Coumadin are not eligible for study; (patients on non-coumadin anticoagulants [Lovenox, Xarelto, etc.] are eligible for study; patients on Coumadin who can be transitioned to Lovenox prior to starting study treatments will be eligible)Xx_NEWLINE_xXAnti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agentsXx_NEWLINE_xXSubject is receiving excluded therapy/treatment per protocolXx_NEWLINE_xXPatients may not be receiving any other investigational agent for any purpose concurrently; patients may not require ongoing treatment with (a) gastric pH modifying medications including proton pump inhibitors or H2 blockers (patients may switch to antacids), (b) medications which are known to be sensitive substrates or substrates with a narrow therapeutic index for the P-gp and BCRP transporters and/or (c) medications known to cause corrected QT (QTc) prolongation with risk of TorsadesXx_NEWLINE_xXEXCLUSION - INFUSION: Currently receiving any investigational agents or radiotherapy within 4 weeks prior to entering the studyXx_NEWLINE_xXHistory of receiving more than 2 classes of ADTXx_NEWLINE_xXTREATMENT EXCLUSION: Currently receiving any investigational agents or received any tumor vaccines within the previous six weeksXx_NEWLINE_xXIs currently taking any prohibited medication(s).Xx_NEWLINE_xXPatients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of INC280, and for the duration of the study; patients on non-enzyme-inducing anticonvulsants are eligibleXx_NEWLINE_xXPatients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.Xx_NEWLINE_xXCurrently receiving treatment with any other agent listed on the prohibited medication listXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval inducing torsades de pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment; a list of prohibited drugs with a known risk of TdP is providedXx_NEWLINE_xXPatients receiving proton pump inhibitors which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.Xx_NEWLINE_xXPatients who are receiving any other investigational agents, with the exception of virus-specific cytotoxic T-cells for the treatment of viral infection/reactivation prior to allo BMTXx_NEWLINE_xXTaking cimetidine or allopurinol; if currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxelXx_NEWLINE_xXWomen who are lactating/breastfeeding or who plan to breastfeed while on sudy through 1 week after receiving the last dose of study drugXx_NEWLINE_xXWomen planning to become pregnant while on study through 1 week after receiving the last dose of study drugXx_NEWLINE_xXPatients receiving the following hepatic enzyme-inducing anti-seizure drugs (“EIASD”); for example:\r\n* Carbamazepine\r\n* Oxcarbazepine\r\n* Phenytoin\r\n* Fosphenytoin\r\n* Phenobarbital\r\n* PrimidoneXx_NEWLINE_xXPatients receiving antithymocyte globulin (ATG) or campath within 28 days of infusionXx_NEWLINE_xXPatients receiving anti-thymocyte globulin (ATG) or Campath within 28 days of infusionXx_NEWLINE_xXCurrently receiving other systemic therapy for metastatic colorectal cancerXx_NEWLINE_xXActively receiving chemo-immunotherapyXx_NEWLINE_xXPatients who are receiving any other anti-cancer or investigational drug therapy are ineligibleXx_NEWLINE_xXPatient is receiving unstable or increasing doses of corticosteroids.Xx_NEWLINE_xXALL PATIENTSXx_NEWLINE_xXAre currently receiving other medications intended for the treatment of their malignancy.Xx_NEWLINE_xXCurrently using or planning to use:Xx_NEWLINE_xXCurrently receiving progestin therapy (local, topical, or systemic)Xx_NEWLINE_xXCurrently receiving any prohibited medications including vitamins and herbal supplementsXx_NEWLINE_xXPatients with known adrenal insufficiency, or patients receiving treatment with ketoconazole, abiraterone, or aminoglutethimide.Xx_NEWLINE_xXConcomitant medications\r\n* Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anticonvulsants: Patients who are receiving enzyme-inducing anticonvulsants are not eligible\r\n* Anticoagulants: Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within 7 days of enrollment\r\n* Smoking: Patients must not smoke for 10 days prior to enrollment and for the duration of therapyXx_NEWLINE_xXSubjects currently on anti-coagulation therapy are not eligibleXx_NEWLINE_xXPatients receiving full dose anticoagulative therapyXx_NEWLINE_xXIs currently receiving oral steroid treatment (inhaled steroids are permitted)Xx_NEWLINE_xXPatients receiving other experimental immunotherapyXx_NEWLINE_xXMust have QTc < 460 msec for patients receiving drugs that have a risk of inducing Torsades de Pointes within 7 days prior to registration for protocol therapyXx_NEWLINE_xXCorticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.Xx_NEWLINE_xXPatients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this studyXx_NEWLINE_xXPatients who have previously received bortezomib or other proteasome inhibitors that did not have a response while receiving the inhibitor are not eligible; patients that responded but had a subsequent relapse are eligibleXx_NEWLINE_xXPatients must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and intrathecal cytarabine are permissibleXx_NEWLINE_xXPatients currently on Pembrolizumab and achieve a less than complete responseXx_NEWLINE_xXExpansion Phase: Patients must have progressed while receiving an androgen-directed therapy, as follows:Xx_NEWLINE_xXCurrently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior)Xx_NEWLINE_xXPatients already receiving hypomethylating agents will be allowed to enroll on the protocol and receive concurrent treatment with vitamin CXx_NEWLINE_xXCurrently or previously being on hydroxyureaXx_NEWLINE_xXPatients who are currently receiving treatment with contraindicated corrected QT interval (QTc) prolonging medications or potent CYP3A4 inducers, if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatmentXx_NEWLINE_xXPatients who are currently receiving another investigational therapy are excludedXx_NEWLINE_xXSubject currently receiving abiraterone and prednisone for CRPC.Xx_NEWLINE_xXPatients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4Xx_NEWLINE_xXActively receiving ibrutinib at either 420 mg (patients enrolled to the escalation arm) or at a stable dose for at least 2 months prior to starting study treatment (patients enrolled to the expansion arm)Xx_NEWLINE_xXFemale patients who intend to donate eggs and male patients who intended to donate sperm during the course of this study or for 4 months after receiving the last dose of study treatmentXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are receiving licensed cord blood products (only)Xx_NEWLINE_xXPatients who are receiving unlicensed cord blood products from other banks (only)Xx_NEWLINE_xXHas a history of, or is currently on, dialysis.Xx_NEWLINE_xXPatients receiving other investigational immunotherapy or anti-myeloma drugs within 14 days before enrollment.Xx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowedXx_NEWLINE_xXParticipants may be receiving other immunosuppressants for the prophylaxis or treatment of acute GVHD but if the subject is receiving prednisone for prophylaxis or treatment of acute GVHD it must be at or below 0.5 mg/kg/dXx_NEWLINE_xXAny patient receiving chronic corticosteroid administration prior to study enrollment is ineligibleXx_NEWLINE_xXPatients currently receiving cancer therapy.Xx_NEWLINE_xXConcomitant medications:\r\n* Growth factors that support platelet or white cell number of function must not have been administered within the past 7 days\r\n* Patients with CNS tumors who have not been on a stable or decreasing dose of dexamethasone for the past 7 days\r\n* Patients who are currently receiving another investigational drug\r\n* Patients who are currently receiving other anti-cancer agents\r\n* Allergy or intolerance to agents on this protocol: vincristine, irinotecan, temozolomide, or metformin\r\n* Allergy to cephalosporins\r\n* Patients who have uncontrolled infection, positive blood cultures within the past 48 hours, or receiving treatment for Clostridium difficile infectionXx_NEWLINE_xXCorticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registrationXx_NEWLINE_xXCurrently receiving systemic antibiotic, antiviral, or antifungal therapy for the treatment of an active infectionXx_NEWLINE_xXOther medications:\r\n* Patients receiving other anti-neoplastic agents are excluded\r\n* Patients on enzyme-inducing anticonvulsive agents are excluded\r\n* Patients requiring strong CYP3A4 or PGP inducers or inhibitors are excluded\r\n* Patients requiring anticoagulation or with uncontrolled bleeding are excluded\r\n* Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatmentXx_NEWLINE_xXPatient must currently be receiving systemic PD-1 immunotherapy with pembrolizumab or nivolumab to be eligible; patients who are receiving combination ipilimumab with pembrolizumab or nivolumab are not eligibleXx_NEWLINE_xXPatient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.Xx_NEWLINE_xXReceiving or anticipated to receive medications prohibited in the protocol.Xx_NEWLINE_xXPatient is receiving or plans to receive other investigational therapy and/or is enrolled or plans to enroll in a separate clinical study.Xx_NEWLINE_xXPatients receiving concurrent corticosteroids at the time protocol therapy is initiated other than for physiologic maintenance treatmentXx_NEWLINE_xXPatients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug with the exception of: hydroxyurea (HU) in patients who need to continue this agent to maintain WBC count =< 50,000/mm^3Xx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXPatients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this studyXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; corticosteroids must be held for 24 hours prior to initiation of study therapy\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible; the definition of “investigational” for use in this protocol means any drug that is not licensed by the Food and Drug Administration (FDA)\r\n* Anti-cancer agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible (except leukemia patients who relapsed on maintenance therapy or patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); intrathecal therapy may be given up to one week prior to initiation of study treatment\r\n* Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD meds\r\n* Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus + ACE inhibitors; at least 3 half-lives must have elapsed after the last dose of ACE inhibitors\r\n* Anti-convulsants: Patients who are currently receiving CYP3A4/PgP enzyme inducing anticonvulsants (eg. phenytoin, phenobarbitol, or carbamazepine) are not eligible; stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable; at least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants\r\n* Inhibitors of everolimus metabolism: Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of everolimus metabolism; at least 3 half-lives must have elapsed after the last dose of azolesXx_NEWLINE_xXCurrently receiving or likely to require systemic immunosuppressive therapy from Day -7 to Day 29.Xx_NEWLINE_xXPatients receiving concomitant immunosuppressive agents for medical conditionXx_NEWLINE_xXSubjects receiving metformin or other agents known to increase risk of lactic acidosis.Xx_NEWLINE_xXPatients receiving any concomitant systemic therapy for renal cell cancer are excluded.Xx_NEWLINE_xXIf receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to ScreeningXx_NEWLINE_xXIs currently receiving and able to discontinue erlotinib, gefinitib, or afatinib.Xx_NEWLINE_xXPatients may not be receiving any other anti-cancer therapy.Xx_NEWLINE_xXSubjects receiving anticoagulation therapyXx_NEWLINE_xXSubjects not seeking or receiving potentially curative therapies for cancer.Xx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval if that treatment cannot be either discontinued or switched to a different medication (not known to affect QT interval) prior to cycle 1 day 1 (C1D1)Xx_NEWLINE_xXPatients with secreting tumors must be receiving pharmacologic catecholamine blockadeXx_NEWLINE_xXCurrently enrolled in another interventional study.Xx_NEWLINE_xXPatients may not be receiving any other anti-neoplastic agentsXx_NEWLINE_xXSubject is receiving excluded therapy/treatment per protocolXx_NEWLINE_xXOnly patients with R/R ALL will be eligible for cohort CXx_NEWLINE_xXPatients on bisphosphonates or RANK-L inhibitors may continue receiving these therapies during study treatment; there is no washout period required between the last dose of these therapies and the start of abemaciclibXx_NEWLINE_xXBaseline QTc exceeding 450msec (470msec for females) and / or patients receiving class 1A or class III anti-arrhythmic agents.Xx_NEWLINE_xXColorectal patients must have received prior fluorouracil (5FU), irinotecan and oxaliplatin (any combination) or have a contraindication to receiving these agentsXx_NEWLINE_xXPatients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registrationXx_NEWLINE_xXPatients receiving post-transplant cyclophosphamide as GVHD prophylaxisXx_NEWLINE_xXPatients receiving anti-retroviral therapy or other agents that are contra-indicated with nelfinavir due to drug-drug interactionsXx_NEWLINE_xXPatients who are currently taking any medications for systemic anticoagulation other than aspirin will not be eligibleXx_NEWLINE_xXPatients currently taking anticoagulantsXx_NEWLINE_xXPatients who are on dexamethasone receiving > 4 mg/day in the two weeks prior to admission for intra-cerebral delivery of PVSRIPOXx_NEWLINE_xXPatients receiving prior therapy with HCQXx_NEWLINE_xXPatients with prolactinomasXx_NEWLINE_xXSubject is currently on renal dialysisXx_NEWLINE_xXReceiving renal replacement therapy, hemodialysis, or peritoneal dialysisXx_NEWLINE_xXPatients with any contraindication to receiving rhuGM-CSF based productsXx_NEWLINE_xXPatients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimenXx_NEWLINE_xXReceiving, or received during the four weeks prior to first dose, cytotoxic treatment for their malignancy Receiving, or received during the week prior to first dose, corticosteroids for any reasonXx_NEWLINE_xXBe receiving leflunomide, or artesunate when study treatment is initiated. Note: Subjects who may be receiving leflunomide must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Subjects receiving artesunate must discontinue the use prior to the first dose of study treatment.Xx_NEWLINE_xXPatients must not be receiving any additional medicines being given for the specific purpose of treating cancerXx_NEWLINE_xXReceiving other experimental therapyXx_NEWLINE_xXPatients receiving any concomitant systemic therapy for renal cell cancer are excludedXx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXCurrently receiving radiation or chemotherapyXx_NEWLINE_xXPatients receiving, or unable to stop use at least 1 week prior to receiving the first dose of BMX-001, medications listed in Section 12.2 of the protocol are not eligible.Xx_NEWLINE_xXSubjects must not be concurrently receiving disease-modifying therapy in another therapeutic investigational studyXx_NEWLINE_xXPatients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.Xx_NEWLINE_xXPatients must be actively receiving treatment for their CML with a TKI: imatinib, dasatinib, nilotinib, or bosutinib\r\n* Patients must be on a stable dose of their TKI for at least 1 year prior to enrollment onto trialXx_NEWLINE_xXAt enrollment, patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXAre currently receiving other medications or radiation intended for the treatment of their malignancyXx_NEWLINE_xXCurrently taking a concomitant medication, other than a premedication, that is:Xx_NEWLINE_xXIs currently receiving another investigational therapyXx_NEWLINE_xXPatients who are currently taking Coumadin or Coumadin derivativesXx_NEWLINE_xXPatient is receiving any azole.Xx_NEWLINE_xXPatients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within 2 weeks prior to starting treatmentXx_NEWLINE_xXPatient is currently participating in an Immunocore-sponsored study of IMCgp100 and is actively receiving IMCgp100. Patient must have fulfilled all required assessments in the parent study (unless the study is being terminated)Xx_NEWLINE_xXPatient is currently receiving clinical benefit from the treatment with IMCgp100, as determined by the principal investigator from the parent studyXx_NEWLINE_xXConcomitant Medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* CYP3A4 active agents: Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors (erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John’s wort)\r\n* Patients who are receiving systemic therapeutic treatment anticoagulation are not eligible; patients receiving prophylactic systemic anticoagulation will be allowed with heparin or low-molecular-weight heparin (LMWH) as long as eligibility PT/INR requirements are met; concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg. clopidogrel) are not allowed\r\n* Enzyme-inducing anticonvulsants: Patients must not have received enzyme–inducing anticonvulsants within 14 days prior to enrollment \r\n* QTc Agents: Patients who are receiving drugs that prolong QTc are not eligibleXx_NEWLINE_xXParticipant is receiving medication(s) that might affect immune functionXx_NEWLINE_xXPatients with renal failure currently requiring dialysis of any kind are not eligibleXx_NEWLINE_xXPatients currently receiving chemotherapy/biologic/immunotherapy as these need to be held during FFSRTXx_NEWLINE_xXPatients receiving anticoagulants that are unable to be discontinuedXx_NEWLINE_xXPART 2 GROUP 1 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibitedXx_NEWLINE_xXPART 2 GROUP 1 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolismXx_NEWLINE_xXPART 2 GROUP 2A EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibitedXx_NEWLINE_xXPART 2 GROUP 2A EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolismXx_NEWLINE_xXPART 2 GROUP 3 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibitedXx_NEWLINE_xXPART 2 GROUP 3 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolismXx_NEWLINE_xXPatients receiving systemic corticosteroids are NOT eligible for either StratumXx_NEWLINE_xXPatients who are currently receiving another investigational drug are NOT eligible for either StratumXx_NEWLINE_xXPatients who are currently receiving other anti-cancer/devices agents are NOT eligible for either StratumXx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients who are receiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving active immunosuppressive therapy.Xx_NEWLINE_xXIn the first 5 patients enrolled in treatment groups on part B of this study (receiving combination ipilimumab and nivolumab), patients may have had 1-0 prior lines of systemic therapy after being diagnosed with metastatic disease; this restriction will be lifted in all subsequent cohorts of patients treated on part BXx_NEWLINE_xXIf patients are taking systemic therapy for cGVHD at the time of enrollment, they must be receiving stable or tapering doses within the previous 4 weeks; patients are not required to have completed a course of steroids prior to enrollmentXx_NEWLINE_xXCurrently receiving investigational agents that are intended as treatments of recurrent GBM.Xx_NEWLINE_xXReceiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocolXx_NEWLINE_xXPatients must be currently receiving ibrutinib for at least 6 months prior to enrollment in the study and:\r\n* Not experiencing any >= grade 2 non-hematologic ibrutinib-related toxicity\r\n* The best response to ibrutinib therapy must not have exceeded partial response or stable disease (i.e. no complete response [CR] or complete response with incomplete marrow recovery [CRi])\r\n* Note: patients carrying a deletion at chromosome 17p (i.e. deletion [del][17p]), and/or tumor protein (TP)53, Bruton's tyrosine kinase (BTK), and at the phospholipase C, gamma 2 (PLCgamma 2) loci mutations, will be eligible if they are receiving frontline therapy with ibrutinibXx_NEWLINE_xXPatients who are currently receiving any other experimental agent, must have stopped other experimental agents at least 21 days prior to 1st study doseXx_NEWLINE_xXPatients receiving systemic treatment with any immunosuppressive medication.Xx_NEWLINE_xXPatients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following:Xx_NEWLINE_xXCurrently receiving active therapy for other neoplastic disordersXx_NEWLINE_xXReceipt of sunitinib within 3 months of receiving tremelimumabXx_NEWLINE_xXSubjects must not be receiving any chemotherapy agents (except hydroxyurea)\r\n* Intrathecal methotrexate and cytarabine are permissibleXx_NEWLINE_xXPatients receiving chronic steroids and or immunosuppressionXx_NEWLINE_xXPatients who are or are not receiving bisphosphonates or denosumab are eligible; bisphosphonates or denosumab should not be initiated after registration and during active treatmentXx_NEWLINE_xXPatients currently receiving active therapy for other neoplastic disordersXx_NEWLINE_xXCurrently use medications known to cause QT prolongation or Torsades de Pointes.Xx_NEWLINE_xXPatients currently receiving any other standard or investigational therapy for the treatment of AMLXx_NEWLINE_xXSubjects currently receiving H2-blocker or proton pump inhibitors (or unable to stop at least 5 days prior to the first treatment).Xx_NEWLINE_xXSubjects currently receiving (or unable to stop using prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inhibitors of CYP3A or CYP2C19 must stop at least 1 week prior to taking MSC2490484A. Subjects receiving potent inducers of CYP3A or CYP2C19 must stop at least 3 weeks prior to taking MSC2490484A. Those receiving drugs mainly metabolized by CYP3A with a narrow therapeutic index as judged by the Investigator (and after optional consultation with the Sponsor) must stop at least one day prior to taking MSC2490484A.Xx_NEWLINE_xXPatients receiving treatment with any enzyme-inducing anticonvulsantXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n* CYP2C19 agents: patients who are currently receiving drugs that are strong CYP2C19 inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligibleXx_NEWLINE_xXIs currently taking any prohibited medication(s)Xx_NEWLINE_xXPatients who are receiving other investigational drugs 14 or fewer days before enrollmentXx_NEWLINE_xXPatients receiving anti-coagulation therapy are eligible as long as anti-coagulation regimen has been stable for > 1 monthXx_NEWLINE_xXPatients receiving cytotoxic agents will be evaluated by the PI or his designee for eligibility suitabilityXx_NEWLINE_xXMust not be currently receiving any investigational drugsXx_NEWLINE_xXPatients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusionXx_NEWLINE_xXPatients currently on beta blockersXx_NEWLINE_xXFor patients with type II diabetes receiving only oral anti-hyperglycemic therapy (patients receiving insulin are not eligible), the following are required at screening:\r\n* HbA1c < 8.5 % or IFCC < 69.4 mmol/mol\r\n* Stable regimen of oral anti-hyperglycemic therapy without insulin usage for at least 3 weeks prior to first study treatment\r\n* Fasting plasma glucose levels =< 160 mg/dL (8.88 mmol/L) and no hypoglycemia (blood sugar [BS] < 60) during home monitoring for at least 1 week prior to study entryXx_NEWLINE_xXPatient may be receiving bone targeted agentsXx_NEWLINE_xXPatients may not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)Xx_NEWLINE_xXPatients who are currently receiving enzyme inducing anticonvulsants are not eligibleXx_NEWLINE_xXPatients who are currently receiving angiotensin-converting enzyme (ACE) inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with temsirolimus + ACE inhibitorsXx_NEWLINE_xXPatients taking sorivudine or brivudine must be off of these drugs for 4 weeks prior to starting capecitabine; patients taking cimetidine must have this drug discontinued; ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine if necessary; if patient is currently receiving allopurinol, must discuss with principal investigator (PI) to see of another agent may substitute for itXx_NEWLINE_xXConcomitant medications\r\n* Corticosteroids: patients receiving corticosteroids that have not been on a stable or decreasing dose for at least 7 days prior to enrollment are not eligible\r\n* Investigational drugs: patients cannot receive other investigational drugs while on this study\r\n* Anti-graft-versus-host disease (GVHD) drugs post-transplant: patients receiving cyclosporine, tacrolimus or other GVHD agents are not eligibleXx_NEWLINE_xXPatients who have already started or received multi-drug consolidation regimen post-transplant expect for patients receiving up to 4 months of single agent  lenalidomide maintenanceXx_NEWLINE_xXConcomitant medications: the following drugs need to be stopped at the time of beginning therapy: patient cannot be on liver enzyme inducing anticonvulsants; patients must not have received growth factors to support the number or function of white cells or platelets within the past 7 days and pegfilgrastim within the past 14 days; patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug)Xx_NEWLINE_xXAngiotensin-converting enzyme (ACE) inhibitors: patients who are currently receiving ACE inhibitors are not eligibleXx_NEWLINE_xXTREATMENT: Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeksXx_NEWLINE_xXCurrently receiving or scheduled to receive any other therapies intended to treat the newly diagnosed glioma prior to the MLA and the first post-MLA blood collection for correlative studiesXx_NEWLINE_xXPatients must either:Xx_NEWLINE_xXPrior history of receiving afatinibXx_NEWLINE_xXPatients who are currently receiving and responding to a different course of anti-neoplastic therapy, within the limits of acceptable toxicity per standard clinical practice, may not be enrolled to this studyXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.Xx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligible.Xx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligible.Xx_NEWLINE_xXPatients actively receiving insulin are excluded unless approved by the investigational new drug (IND) medical monitor, IND sponsor, and the study principal investigator (PI)Xx_NEWLINE_xXSteroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior enrollment in the studyXx_NEWLINE_xXPatients who are currently taking metformin; prior metformin use is allowed if last dose was 3 months previous to this trialXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing (except ALK inhibitors)Xx_NEWLINE_xXPatients receiving prior therapy with RGF, VOR, and/or HCQXx_NEWLINE_xXTREATMENT: Patients receiving systemic corticosteroid within 48 hours of CTL infusionXx_NEWLINE_xXSubjects receiving class III antiarrhythmic medicationsXx_NEWLINE_xXPatients receiving Anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of treatment with Viralym-A.Xx_NEWLINE_xXSubjects with a diagnosis of metastatic disease who are currently receiving treatment or who have not been deemed in remissionXx_NEWLINE_xXOther nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.Xx_NEWLINE_xXShares the same address as a currently enrolled participantXx_NEWLINE_xXPatients receiving anti-thymocyte globulin (ATG), or Campath within 28 days of CMV reactivationXx_NEWLINE_xXPatients receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXPatients with any contraindication to receiving rhuGM-CSF based productsXx_NEWLINE_xXReceiving supplementary continuous oxygenXx_NEWLINE_xXPatients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXHave contraindications to receiving doxorubicin hydrochloride (HCl).Xx_NEWLINE_xXPatients receiving anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollmentXx_NEWLINE_xXPatients who are currently taking or plan to take curcumin during the studyXx_NEWLINE_xXPatients must have:Xx_NEWLINE_xXPatients who are in-patients.Xx_NEWLINE_xXContraindication to receiving HCQ or TACEXx_NEWLINE_xXPatients who are receiving or may receive future treatment with PI3K or TNFalpha inhibitorsXx_NEWLINE_xXCurrently taking phenytoin or phenobarbitalXx_NEWLINE_xXCurrently taking cholestyramine or orlistatXx_NEWLINE_xXPatients who are actively receiving steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) on a chronic basis and who are unwilling and/or unable to discontinue while on study therapy are NOT eligible for participation; NOTE: patients must have discontinued steroids or NSAIDs for 1 week prior to registration to be considered eligible for participationXx_NEWLINE_xXPatients who are receiving cyclosporine, tacrolimus, or other chronic immunosuppressive agents are NOT eligible for participationXx_NEWLINE_xXPatients receiving cytotoxic agents will be evaluated by the PI or his designee for eligibility suitability (Turnstile I)Xx_NEWLINE_xXPatients being treated with certain drugs not acceptable while receiving CFI-400945 fumarate.Xx_NEWLINE_xXPatients who are receiving an emergency colonoscopyXx_NEWLINE_xXPatients who are currently taking nonsteroidal anti-inflammatory drugs (NSAIDs) and/or opioid pain medications must remain on a stable dosage throughout the duration of the studyXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agentsXx_NEWLINE_xXPatients who are currently taking omega-3 fatty acidsXx_NEWLINE_xXPatients must not be currently receiving any chemotherapy agents (except hydroxyurea)\r\n* Intrathecal cytarabine (ARA-C) and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system)\r\n* Patients cannot have received more than 3 prior lines of therapy for their hematologic malignancy; patient may have previously had azacitidine or decitabine and still be eligibleXx_NEWLINE_xXPatients receiving SRS to resection bedXx_NEWLINE_xXCurrently taking cytotoxic chemotherapy; however, patients receiving non-investigational hormone therapy, lapatinib, and/or trastuzumab are eligible provided these medicines are at a stable dose and were begun more than 30 days prior to the first IT injectionXx_NEWLINE_xXPatient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternativesXx_NEWLINE_xXPatient has participated in a Novartis sponsored combination trial where pasireotide was dispensed in combination with another study medication and is still receiving combination therapy. (only patients receiving pasireotide monotherapy can be included)Xx_NEWLINE_xXCurrently taking metformin, sulfonyureas, thiazolidenediones or insulin for any reasonXx_NEWLINE_xXPatients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible; patients receiving cytotoxic agents will be evaluated by the PI or his designeeXx_NEWLINE_xXPatients who are receiving monoamine oxidase (MAO) inhibitorsXx_NEWLINE_xXCOHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 monthsXx_NEWLINE_xXPatients who may be receiving any enzyme-inducing antiepileptic drugs (EIAED) within 2 weeks prior to registration, or any other prohibited medications within the washout period prior to registrationXx_NEWLINE_xXPatients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior); all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4Xx_NEWLINE_xXThose receiving prior immunotherapy must meet all of the following conditions:Xx_NEWLINE_xXPatients currently receiving chronic corticosteroid treatment (longer than 8 weeks duration) for management of pre-existing adverse events, or patients with a history of chronic corticosteroid treatment longer than 8 weeks' duration for AEs within 6 months of Screening are excludedXx_NEWLINE_xXINCLUSION CRITERIA\n\n        -Patients must be greater than or equal to 12 months and ? 21 years of age at the time of\n        study enrollment.\n\n        Patients must have one of the following:\n\n        Leukemia\n\n          -  Bone marrow involvement defined as ALL ? 25% blasts (M2 or M3) with or without\n             extramedullary involvement.\n\n          -  Refractory bone marrow involvement defined as MRD ? 0.1% blasts done at a COG-approved\n             MRD testing lab after most recent treatment regimen. in the bone marrow (M23) and any\n             CNS status. OR\n\n          -  Newly diagnosed patients (T or B-cell ALL) with refractory bone marrow involvement\n             after Consolidation therapy are eligible.\n\n          -  First relapse B-cell ALL patients are eligible with refractory disease.\n\n          -  Second or greater relapse B-cell patients are eligible at time of relapse or with\n             refractory disease.\n\n          -  First or greater relapse T-cell ALL patients are eligible at time of relapse or with\n             refractory disease.\n\n          -  Isolated CNS 2 or 3 patients with < 0.1% MRD bone marrow involvement are not eligible.\n\n        Lymphoma\n\n          -  Patient must have relapsed or refractory lymphoblastic lymphoma or peripheral T-cell\n             lymphoma.\n\n          -  Patient must have histologic verification of disease at original diagnosis.\n\n          -  Patient must have evaluable or measurable disease documented by clinical or\n             radiographic criteria or bone marrow disease present at study entry.\n\n          -  Patients may have CNS 2 or 3 disease\n\n        Karnofsky greater than or equal to 50% for patients > 16 years of age and Lansky greater\n        than or equal to 50 for patients ? 16 years of age.\n\n        Patients must have fully recovered from the acute toxic effects of all prior anti-cancer\n        chemotherapy.\n\n        Patients with leukemia or lymphoma who relapse while receiving maintenance chemotherapy\n        will not be required to have a waiting period before enrollment onto this study.\n\n        At least 14 days must have elapsed after the completion of cytotoxic therapy, with the\n        exception of hydroxyurea.\n\n        Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth\n        factor (e.g. Neulasta) or 7 days for short-acting growth factor.\n\n        Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent.\n        For agents that have known adverse events occurring beyond 7 days after administration,\n        this period must be extended beyond the time during which adverse events are known to\n        occur. The duration of this interval must be discussed with the study chair\n\n        Immunotherapy: At least 30 days after the completion of any type of immunotherapy, e.g.\n        tumor vaccines. or chimeric antigen receptor T cell (CART) therapy or tumor vaccines.\n\n        Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the\n        last dose of a monoclonal antibody. (ie: Rituximab = 66 days, Epratuzumab = 69 days).\n        Patients must have been off blinatumomab infusion for at least 4 days and all drug-related\n        toxicity must have resolved to grade 2 or lower as outlined in the inclusion and exclusion\n        criteria\n\n        XRT: At least 14 days after local palliative XRT (small port); At least 84 days must have\n        elapsed if prior TBI, craniospinal XRT or if greater than or equal to 50% radiation of\n        pelvis; At least 42 days must have elapsed if other substantial marrow radiation.\n\n        Stem Cell Infusion: No evidence of active graft vs. host disease and at least 84 days must\n        have elapsed after transplant or stem cell infusion.\n\n        Adequate Bone Marrow Function Defined as: Blood counts are not required to be normal prior\n        to enrollment on trial. However, platelet count must be greater than or equal to 20,000/mm3\n        to initiate therapy (may receive platelet transfusions). Patients should not be known to be\n        refractory to red blood cell or platelet transfusions.\n\n        Adequate Renal Function Defined as:\n\n          -  Creatinine clearance or radioisotope GFR greater than or equal to 70ml/min/1.73 m2 or\n\n          -  Normal serum creatinine based on age and gender.\n\n        Adequate Liver Function Defined as:\n\n          -  Total bilirubin (sum of conjugated + unconjugated) must be less than or equal to 1.5 x\n             normal per institutional normal values for age.\n\n          -  SGPT (ALT) and SGOT (AST) must be less than 3 x institutional upper limit of normal\n             (Grade 1 or less per CTCAE 4).\n\n             --GGT must be less than 2.5 x institutional upper limit of normal (Grade 1 or less per\n             CTCAE 4).\n\n          -  Serum albumin greater than or equal to 2 g/dL.\n\n          -  The hepatic requirements may be waived for patients with elevations clearly due to\n             leukemic infiltration after consultation with the Study Chair or Vice Chair.\n\n          -  Fasting or non-fasting serum triglyceride level ? 300 mg/dL and serum cholesterol\n             level ? 300 mg/dL.\n\n        Adequate Cardiac Function Defined As:\n\n          -  Shortening fraction of ? 27% by echocardiogram, or\n\n          -  Ejection fraction of ? 50% by gated radionuclide study.\n\n        Adequate Pulmonary Function Defined as:\n\n          -  Pulse oximetry > 94% on room air (> 90% if at high altitude)\n\n          -  No evidence of dyspnea at rest and no exercise intolerance.\n\n          -  Baseline chest x-ray with no evidence of active infectious disease or pneumonitis.\n\n        Reproductive Function\n\n          -  Female patients of childbearing potential must have a negative urine or serum\n             pregnancy test confirmed prior to enrollment.\n\n          -  Female patients with infants must agree not to breastfeed their infants while on this\n             study.\n\n          -  Male and female patients of child-bearing potential must agree to use an effective\n             method of contraception approved by the investigator during the study.\n\n          -  Random or fasting glucose within the upper limits of normal for age. If the initial\n             blood glucose is non-fasting and above normal limits a fasting glucose can be obtained\n             and must be within the upper limits of normal for age.\n\n        EXCLUSION CRITERIA\n\n          -  Corticosteroids: Patients receiving corticosteroids who have not been on a stable or\n             decreasing dose of corticosteroid for at least 7 days prior to enrollment are not\n             eligible.\n\n          -  Investigational Drugs: Patients who are currently receiving another investigational\n             drug are not eligible. The definition of \investigational\ for use in this protocol\n             means any drug that is not licensed by the FDA, Health Canada or the Therapeutic Goods\n             Administration to be sold in the countries they govern. (United States, Canada and\n             Australia)\n\n          -  Anti-cancer Agents: Patients who are currently receiving or may receive while on\n             therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible\n             [except leukemia patients receiving hydroxyurea, which may be continued until 24 hours\n             prior to start of protocol therapy]. Intrathecal chemotherapy (at the discretion of\n             the primary oncologist) may be given up to one week prior to the initiation of study\n             therapy.\n\n          -  Anti-GVHD or agents to prevent organ rejection post-transplant: Patients who are\n             receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host\n             disease post bone marrow transplant or organ rejection post transplant are not\n             eligible for this trial. At least 3 half-lives must have elapsed after the last dose\n             of GVHD meds.\n\n          -  Anticoagulants: Patients who are currently receiving therapeutic anticoagulants\n             (including aspirin, low molecular weight heparin, and others) are not eligible. At\n             least 3 half-lives must have elapsed after the last dose of anticoagulants.\n\n          -  Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving\n             ACE inhibitors are not eligible due to the development of angioneurotic edema-type\n             reactions in some subjects who received concurrent treatment with temsirolimus + ACE\n             inhibitors. At least 3 half-lives must have elapsed after the last dose of ACE\n             inhibitors.\n\n          -  Calcium Channel Blockers: Patients who are currently receiving Calcium Channel\n             Blockers are not eligible due to the development of angioneurotic edema-type reactions\n             in some subjects who received concurrent treatment with temsirolimus + Calcium Channel\n             Blockers. At least 3 half-lives must have elapsed after the last dose of Calcium\n             Channel Blockers.\n\n          -  Enzyme inducing Anti-convulsants: Patients who are currently receiving enzyme inducing\n             anticonvulsants (ie phenytoin, phenobarbitol, or carbamazepine) are not eligible.\n             Stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or\n             levetiracetam) prior to study entry is acceptable. At least 3 half-lives must have\n             elapsed after the last dose of enzyme inducing anti-coagulants.\n\n          -  Patients receiving treatment with azoles such as fluconazole or voriconazole which are\n             potent inhibitors of temsirolimus metabolism. At least 3 half-lives must have elapsed\n             after the last dose of azoles.\n\n          -  Patient with Burkiett's leukemia and /or lymphoma are not eligible.\n\n        Infection Criteria\n\n        Patients are excluded if they have:\n\n          -  Positive blood culture within 48 hours of study enrollment;\n\n          -  Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection.\n             Fever that is determined to be due to tumor burden is allowed if patients have\n             documented negative blood cultures for at least 48 hours prior to enrollment and no\n             concurrent signs or symptoms of active infection or hemodynamic instability.\n\n          -  A positive fungal culture within 30 days.\n\n          -  Active fungal, viral, bacterial, or protozoal infection requiring IV treatment.\n             Chronic prophylaxis therapy to prevent infections is allowed.\n\n        Patients with Down syndrome and Fanconi Anemia are excluded.\n\n        Patients will be excluded if they have significant concurrent disease, illness, psychiatric\n        disorder or social issue that would compromise patient safety or compliance with protocol\n        treatment or required observations, interfere with consent, study participation, follow up,\n        or interpretation of study results.\n\n        Patients with known optic nerve and/or retinal involvement (because it may not be possible\n        to safely delay irradiation) are not eligible. Patients presenting with visual disturbances\n        by history or physical exam should have an ophthalmological exam and, if indicated, an MRI\n        to determine optic nerve or retinal involvement.Xx_NEWLINE_xXPatients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to registrationXx_NEWLINE_xXPatients who have had prior chemotherapy, experimental agents for prostate cancer, or patients receiving more than 8 weeks of prior hormone therapy will be excludedXx_NEWLINE_xXSplenectomized patientsXx_NEWLINE_xXPatients in first remission are eligibleXx_NEWLINE_xXPatients must undergo a peritoneal scan documenting at least one working intraperitoneal port prior to receiving chemotherapyXx_NEWLINE_xXPatients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have received either agent within 90 days of entry are ineligibleXx_NEWLINE_xXPre-existing bilateral sensorineural hearing loss at >90dB at any frequency from 250-8000Hz as assessed by a comprehensive audiometric evaluation for patients receiving cisplatin. This criteria will not apply to patients receiving carboplatin.Xx_NEWLINE_xXPatients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible; patients receiving cytotoxic agents will be evaluated by the PI or his designee as to suitable eligibility (Turnstile I)Xx_NEWLINE_xXPatients must have either:Xx_NEWLINE_xXSubject is receiving anticoagulation; washout period of 7 daysXx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXReceiving other treatments for the condition (with exceptions and time limits)Xx_NEWLINE_xXPatients receiving unstable or increasing doses of corticosteroidsXx_NEWLINE_xXPatients receiving treatment with any enzyme-inducing anticonvulsantXx_NEWLINE_xXPatients receiving other investigational drugs for GVHD. Co-enrollment in other clinical trials that do not include experimental GVHD therapies is allowedXx_NEWLINE_xXPatient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.Xx_NEWLINE_xXReceiving treatment with any medication known to produce QT prolongation within 7 days of study entryXx_NEWLINE_xXPatients must not be receiving active immunosuppressive therapy.Xx_NEWLINE_xXPatients receiving any other investigational agents or anti-cancer agents within 30 days other than mibefradil dihydrochloride, hypofractionated RT, or corticosteroids as described in this clinical protocol during treatmentXx_NEWLINE_xXPatients receiving any statin except pravastatin or rosuvastatinXx_NEWLINE_xXChronic adrenal failure or is receiving concurrent long-term corticosteroid therapy.Xx_NEWLINE_xXPatient is currently enrolled in a Novartis-sponsored, CD&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent studyXx_NEWLINE_xXPatient is receiving everolimus in combination with an unapproved or experimental treatmentXx_NEWLINE_xXPrior history of receiving pazopanib treatmentsXx_NEWLINE_xXPatients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)Xx_NEWLINE_xXPatient is currently receiving medication(s) that are principally metabolized via the cytochrome P450 3A4 enzyme pathway.Xx_NEWLINE_xXPatients who are currently receiving treatment with medication that has the potential to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients who eitherXx_NEWLINE_xXPatients who are receiving concurrent combination with sorafenib (Nexavar) and capecitabine in their originating Study 12444 (RESILIENCE) will be eligible.Xx_NEWLINE_xXCurrently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.Xx_NEWLINE_xXCurrently receiving or has received treatment with systemic steroids in the following dosages within 30 days prior to administration of the first study vaccination.Xx_NEWLINE_xXPatients must not be currently receiving other anti-cancer agentsXx_NEWLINE_xXParticipant is not suitable for receiving ocular steroids with conditions as described in the protocol.Xx_NEWLINE_xXPatients receiving therapeutic non-Coumadin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulantXx_NEWLINE_xXCurrently receiving active therapy for other neoplastic disordersXx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.Xx_NEWLINE_xXPatients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on study.Xx_NEWLINE_xXWomen receiving a “nipple delay” procedure prior to mastectomyXx_NEWLINE_xXCurrently taking lithium therapyXx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on studyXx_NEWLINE_xXPatients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on studyXx_NEWLINE_xXPatients must not be receiving other medications known to prolong the QT interval at the time of study entry or while on protocol therapyXx_NEWLINE_xXKnown allergic reaction to talimogene laherparepvec, paclitaxel, aromatase inhibitors, tamoxifen, fulvestrant, or any of their components; an exception is made if the patient will not be receiving the offending agent/component (i.e. a patient who is allergic to paclitaxel but will be receiving endocrine therapy is eligible)Xx_NEWLINE_xXPart 2: currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)Xx_NEWLINE_xXConcomitant medications: \r\n* Investigational Drugs: Subjects who are currently receiving another investigational drug are not eligible \r\n* Anti-cancer Agents: Subjects who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-graft-versus-host disease (GVHD) agents post-transplant: Subjects who are receiving cyclosporine, tacrolimus, or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* Medications interfering with metabolism:\r\n** Medications which interfere with CYP3A4 and CYP2C8 metabolism, which metabolize nab-paclitaxel: subjects using these agents are not eligible for this trial; paclitaxel is metabolized by CYP3A4 and CYP2C8, so strong inhibitors or inducers of these enzymes should be avoided\r\n*** Note on use of trimethoprim/sulfamethoxazole: Trimethoprim/sulfamethoxazole should not be administered concomitantly with abraxane/gemcitabine, and patients must be monitored closely for toxicitiesXx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXRENAL & BLADDER: Currently enrolled in another interventional studyXx_NEWLINE_xXSubject is receiving prohibited medications or treatments that cannot be discontinued/replaced by an alternative therapyXx_NEWLINE_xXPatient is currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and whose treatment cannot be either discontinued or switched to a different medication prior to starting treatment with the study drug.Xx_NEWLINE_xXPatients actively receiving insulin are excluded unless approved by the investigational new drug (IND) medical monitor, IND sponsor, and the study principal investigator (PI)Xx_NEWLINE_xXPatient who is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXPatients who are receiving any other investigational agents require a 4 week washout period; patients who have received cellular or gene therapy at any time are not eligibleXx_NEWLINE_xXPatients requiring escalation of the corticosteroid dose will be excluded, but patients receiving a stable or decreasing dose for at least one week will be eligibleXx_NEWLINE_xXPatients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients who are currently receiving another investigational drugXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agentsXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXSubjects receiving investigational study drug for any indication or immunological-based treatment for any reason (Filgrastim may be used for prevention of severe neutropenia).Xx_NEWLINE_xXReceiving any medications that prolong the QTc and have a known risk for Torsades de pointes; providers should use caution with drugs with possible increased risk for Torsades de pointes; NOTE: patient will be eligible if they can be taken off these medications prior to initiation of therapy and no less than 4 half-lives of the medicationXx_NEWLINE_xXPatients may not use herbal or non-traditional medications while receiving AMG 232 therapy; all herbal medicines (e.g., St. John’s wort), vitamins, and supplements consumed by the subject within the 30 days prior to receiving the first dose of AMG 232 should be reviewed by the principal investigatorXx_NEWLINE_xXBe receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: Subjects who may be receiving leflunomide or letermovir must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Subjects receiving artesunate must discontinue the use prior to the first dose of study treatment.Xx_NEWLINE_xXPatients with TE event occurring > 6 months prior to enrollment and receiving active anticoagulationXx_NEWLINE_xXWomen who are lactating/breast feeding or who plan to breastfeed while on study through 1 week after receiving the last dose of study drugXx_NEWLINE_xXPatients who are currently receiving another investigational drugXx_NEWLINE_xXPatients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy and intrathecal chemotherapy)Xx_NEWLINE_xXPatients currently being treated with quinacrine or drugs related to quinacrineXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatmentXx_NEWLINE_xXSubjects must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and cytarabine are permissibleXx_NEWLINE_xXPatients currently receiving any medication known to induce central serous chorioretinopathy which in the opinion of the principal investigator, would make the administration of study drug hazardousXx_NEWLINE_xXPatients must be willing and able to check and record daily blood pressure readings if receiving cediranibXx_NEWLINE_xXReceiving phenytoinXx_NEWLINE_xXPatients who are currently receiving another investigational drugXx_NEWLINE_xXPatients receiving medications for treatment of left ventricular systolic dysfunctionXx_NEWLINE_xXReceiving warfarin therapy and cannot tolerate drug substitutionXx_NEWLINE_xXPatients may not be receiving any other investigational agents with the intention to treat their cancer (imaging trials are acceptable)Xx_NEWLINE_xXPatients receiving any medications or substances to treat active infectionXx_NEWLINE_xXFull anti-coagulant therapy Coumadin; patients may be receiving therapeutic Lovenox, Fragmin, or other heparin product that does not require laboratory monitoringXx_NEWLINE_xXPatients may not be receiving any steroids or other anti-immune therapy at the time of registrationXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients receiving highly active antiretroviral therapy (HAART) treatmentXx_NEWLINE_xXParticipants receiving the following medications or treatments within the 6 weeks (42 days) prior to consenting; these medication and treatments may not be re-started at any time throughout the study in order to be remain eligible:\r\n* Breast tumor resection surgery (reconstructive surgery permitted)\r\n* Chemotherapy\r\n* Radiation therapy\r\n* Allergy desensitization injections\r\n* Growth factors (Procrit, Aranesp, Neulasta)\r\n* Other agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents)\r\n* Any investigational medicationXx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on studyXx_NEWLINE_xXPatients who were receiving corticosteroids have to receive a stable or decreasing dose for at least 14 days before study entryXx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the\n             potential to prolong the QT interval and the treatment cannot be either discontinued\n             or switched to a different medication before starting rociletinibXx_NEWLINE_xXPatients who are currently receiving chemotherapy, radiation therapy or are enrolled in another therapeutic clinical trialXx_NEWLINE_xXPatients receiving medications that have the potential to prolong the QT intervalXx_NEWLINE_xXALL PATIENTS:Xx_NEWLINE_xXCurrently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXConcomitant medications \r\n* Corticosteroids: patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible\r\n* Patients who have received previous treatment with IMGN901 are not eligible\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-graft-versus-host disease (GVHD) or agents to prevent organ rejection post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trialXx_NEWLINE_xXPatients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this studyXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents with the exception of those delineated in the eligibility criteriaXx_NEWLINE_xXSubject is currently receiving treatment with a medication that has a known risk to prolong the QT interval or induce Torsades de Pointes and the treatment cannot be discontinued or switched to a different medication prior to randomizationXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are receiving drugs that prolong the QTc are not eligibleXx_NEWLINE_xXPatients receiving chronically dosed corticosteroids within 7 days prior to enrollment are not eligible for this trialXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are receiving anti-hypertensive medications for control of blood pressure at the time of enrollment are not eligible for this trialXx_NEWLINE_xXPatients who are currently receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs or anti-platelet agents are not eligibleXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); patients with acute lymphoblastic leukemia may receive intrathecal therapyXx_NEWLINE_xXMust be either initiating therapy with romidepsin (Arm A) or currently receiving romidepsin with documented stable disease (SD) or partial response (PR) (Arm B)Xx_NEWLINE_xXPatients who are receiving dexamethasone must be on a stable dose for at least 1 week prior to study entryXx_NEWLINE_xXNot currently receiving therapyXx_NEWLINE_xXReceiving umbilical cord bloodXx_NEWLINE_xXNot currently receiving other investigational drugsXx_NEWLINE_xXPatients must not be currently receiving immunosuppressive drugs such as corticosteroids, tacrolimus or cyclosporineXx_NEWLINE_xXPatients receiving nilotinib 200 mg PO BID or a lower dose are not eligibleXx_NEWLINE_xXEligibility of patients receiving any medications or substances known to affect or with potential to affect the activity or pharmacokinetics of temsirolimus and/or sorafenib will be determined following review of the case by the study chair; efforts should be made to switch patients who are taking enzyme-inducing anti-convulsant agents to other medicationsXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXA 7-day washout period is required if patients are currently using another oral topical treatment for mouth lesions; patients currently using clobetasol oral topical treatment are not eligible for this studyXx_NEWLINE_xXReceiving mitotane within 6 months of enrolling on the studyXx_NEWLINE_xXPatients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXConcomitant medications restrictions:\r\n* Growth factor(s): Must not have received within 7 days of entry onto this study\r\n* Steroids: Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 7 days\r\n* Study Specific: Patients must not be currently taking nonsteroidal anti-inflammatory drugs (NSAIDs), clopidrogel, dipyridamole or aspirin therapy > 81 mg/dayXx_NEWLINE_xXPatients receiving the formulated capsules must have a body surface area (BSA) >= 0.63 m^2 at the time of study enrollmentXx_NEWLINE_xXPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligibleXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents, with the exception of hydroxyurea for patients with ALCL, are not eligibleXx_NEWLINE_xXPatients receiving CoumadinXx_NEWLINE_xXIs currently taking any prohibited medication(s)Xx_NEWLINE_xXThe participant is receiving therapy with any of the following:Xx_NEWLINE_xXFor Cohort B: Is currently receiving any of the following classes of inhibitors of CYP3A4: azole antifungals; macrolide antibiotics; or protease inhibitorsXx_NEWLINE_xXPatients receiving sirolimus (for any indication including GVHD prophylaxis) within 14 days of screening for enrollment.Xx_NEWLINE_xXPatients must not be registered until receiving confirmation from the Southwest Oncology Group (SWOG) Statistical Center that the patient's tissue specimen was adequate for PD-L1 testing; patients must be registered within 7 working days of receiving the e-mail notificationXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXPatients may be:Xx_NEWLINE_xXPatients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior); all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects of CYP3A4Xx_NEWLINE_xXPatients receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXCurrently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab.Xx_NEWLINE_xXCurrently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecidXx_NEWLINE_xXCurrently receiving hormone replacement therapy, unless discontinued prior to screeningXx_NEWLINE_xXSubject is currently receiving treatment with any agent listed on the prohibited medication listXx_NEWLINE_xXFor patients enrolled in Part 2SA who are receiving anti-PD-1 mAb therapy, marrow and hepatic function as defined in criteria 8a and 8b may be up to CTCAE Grade 2 if first reviewed, found to be within acceptable safety parameters for treatment with pembrolizumab, and approved by the Sponsor Medical Monitor.Xx_NEWLINE_xXPatients must not be receiving erythroid stimulating agents (EPO: Procrit, Aranesp)Xx_NEWLINE_xXPatient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment.Xx_NEWLINE_xXIs currently taking any prohibited medication(s)Xx_NEWLINE_xXSubject must currently be participating in an Astellas sponsored, single agent ASP2215 trial, receiving ASP2215 and have not met any discontinuation criteria of the parent study and can enroll into this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.Xx_NEWLINE_xXPatients must have:Xx_NEWLINE_xXPatients who have:Xx_NEWLINE_xXPatients who:Xx_NEWLINE_xXPatients with:Xx_NEWLINE_xXFor inclusion in Cohort 1, mCRPC patients must have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible). NOTE: patients receiving fewer than 2 cycles of taxane based regimen due to intolerance are eligible for cohort 1.Xx_NEWLINE_xXFor inclusion in Cohort 2, mCRPC patients must have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and must have progressed subsequent to receiving ? 2 cycles of a taxane-based regimen for mCRPC.Xx_NEWLINE_xXConcomitant medications: patients receiving anticoagulation should be on stable dose 2 weeks prior to registrationXx_NEWLINE_xXPatients receiving QT prolonging medications (such as ondansetron)Xx_NEWLINE_xXCurrently receiving any prohibited medications including vitamins and herbal supplementsXx_NEWLINE_xXPatients must have:Xx_NEWLINE_xXPatients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans (Refer to Appendix 3)Xx_NEWLINE_xXPatients who do not have GTNXx_NEWLINE_xXFor patients receiving therapeutic anticoagulation: stable anticoagulant regimenXx_NEWLINE_xXPatient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug Ribociclib:Xx_NEWLINE_xXPatients must have:Xx_NEWLINE_xXPatient is currently receiving any of the following substances and cannot be discontinued 7 days prior to start the treatment:Xx_NEWLINE_xXPatient is currently using other antineoplastic agentsXx_NEWLINE_xXPatients who have disease progression during, or after, receiving abiraterone treatment in any setting.Xx_NEWLINE_xXCurrently receiving cancer therapy. Hydroxyurea will be allowed.Xx_NEWLINE_xXIs receiving concomitant treatment with drugs that may interact with capecitabineXx_NEWLINE_xXPatients already receiving treatment with FOLFIRINOX +/- trastuzumab may participate in the study and have their data collected retrospectively if they met inclusion criteria at the start of therapy and sign consent for study participation moving forwardXx_NEWLINE_xXNot currently taking steroidsXx_NEWLINE_xXPatients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligibleXx_NEWLINE_xXSubject must be receiving treatment in an ICU, or in an acute care setting (e.g., ER, RR)Xx_NEWLINE_xXPatients with known immunodeficiency or receiving immunosuppressive therapiesXx_NEWLINE_xXPatient currently receiving treatment with any medications that have the potential to prolong the QT interval and cannot be either discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients receiving any drugs that have potential nephrotoxicity or ototoxicity (such as an aminoglycoside)Xx_NEWLINE_xXOrgan function requirements are not required for enrolled patients who are stage I, PFH and will not be receiving chemotherapyXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anticancer agents are not eligibleXx_NEWLINE_xXPatients who are currently receiving enzyme inducing anticonvulsants are not eligibleXx_NEWLINE_xXPatients who are currently receiving angiotensin-converting enzymes (ACE) inhibitors are not eligibleXx_NEWLINE_xXPatients receiving any of the following medications are not eligible for study:\r\n* Anti-cancer therapy or investigational agents\r\n* Anti-coagulants (except for heparin to maintain the patency of central venous catheters)\r\n* Growth factors for white blood cell, red blood cell or platelet support\r\n* Aspirin (> 81 mg/day)\r\n* Non-steroidal anti-inflammatory drugs\r\n* Clopidogrel (Plavix), dipyridamole (Persantine), or any other drug that inhibits platelet functions\r\n* Anti-convulsants: patients on any anti-convulsant with the exception of VPA are eligible for study entry; it is STRONGLY RECCOMMENED that a neurology consult be obtained to enable discontinuation of all anticonvulsant other than VPA, whenever possibleXx_NEWLINE_xXWomen who are lactating/breast feeding or who plan to breastfeed while on study through 1 week after receiving the last dose of study drugXx_NEWLINE_xXPatients receiving systemic treatment with any immunosuppressive medication.Xx_NEWLINE_xXPatients receiving prohibited concomitant medications at the start of the studyXx_NEWLINE_xXAre receiving chronic therapy with any of the following medications within 7 days prior to enrollment:Xx_NEWLINE_xXKnown, existing coagulopathy or receiving anticoagulantsXx_NEWLINE_xXPatients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug; NOTE: prohibited medications contains drugs that should be used with caution due to possible or conditional risk of Torsades de PointesXx_NEWLINE_xXPatients receiving cyclosporine A, tacrolimus, or sirolimus are not eligible for this study.Xx_NEWLINE_xXPatients receiving anti-cancer therapy within 21 days before MSC treatmentXx_NEWLINE_xXPatients who are receiving other cancer directed therapy at the time of enrollmentXx_NEWLINE_xXPatients receiving bisphosphonatesXx_NEWLINE_xXPatients receiving a haploidentical / T cell-depleted transplant are eligible to follow a modified treatment plan that does not include withdrawal of immunosuppressionXx_NEWLINE_xXPatients who have had repeat craniotomy for tumor therapy after receiving RT and TMZ treatmentXx_NEWLINE_xXSubjects may not be receiving any other study agents concurrently while on this studyXx_NEWLINE_xXPatients who are currently receiving treatment with agents that are known to cause QTc prolongation or inducing Torsade de Pointes in humans and are unable to discontinue or switch to an alternate medicationXx_NEWLINE_xXPatients who are receiving any other anti-cancer or investigational drug therapy are excludedXx_NEWLINE_xXOR for subjects receiving warfarin or LMWH, the subjects must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.Xx_NEWLINE_xXConcomitant medications:\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim)\r\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Patients who are currently receiving the enzyme inducing anticonvulsants: phenytoin, phenobarbital, carbamazepine, oxcarbazepine are not eligible; patients who are currently taking rifampin, voriconazole, itraconazole, ketoconazole, aprepitant, or St. John’s Wort are not eligible\r\n* Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within 7 days of starting protocol therapy\r\n* Patients receiving medications that prolong the QTcXx_NEWLINE_xXWOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXPatients may not be receiving the following medications at the time of first dose of investigational drug:\r\n* Pharmacotherapy for known hepatitis B or C, tuberculosis, or human immunodeficiency virus (HIV) \r\n* Any of the following enzyme inducing anti-epileptic medications (EIAEDs): phenytoin, carbamazepine, oxcarbazepine, phenobarbital\r\n* Other chemotherapy, hormonal therapy, immunotherapy, other investigational agents, or biologic agents for the treatment of cancer except for bisphosphonates or denosumabXx_NEWLINE_xXPatient is currently receiving treatment with QT prolonging medication known to have a risk to induce torsades de pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXCurrent use of a prohibited medication; these include:\r\n* Patients who are receiving treatment with medications that are known to be strong inducers or inhibitors of CYP3A4/5 and CYP3A4/5 substrates with QT prolongation risk that cannot be discontinued prior to study entry\r\n* Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXPatients receiving anti-herpes medication within 1 week prior to initiating HF10 treatment.Xx_NEWLINE_xXParticipants who are receiving any other investigational agents\r\n* Patients who have previously received ibrutinib will be ineligible in the Phase Ib portion of the study of the CLL arm\r\n* MCL patients who have been on ibrutinib for less than 6 months (180 days) from the time of registration are eligible in the Ib portion of the trial; no washout will be requiredXx_NEWLINE_xXPatient currently receiving lithium, steroid, chemotherapy or radiotherapy treatmentXx_NEWLINE_xXPatients must not be receiving therapeutic anticoagulationXx_NEWLINE_xXPatients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients receiving certain medications and/or substances that are prohibited within stated wash-out periodsXx_NEWLINE_xXReceiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.Xx_NEWLINE_xXPatients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatmentXx_NEWLINE_xXMedical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapyXx_NEWLINE_xXPatients currently receiving bone loss prevention treatment (e.g. bisphosphonates, denosumab, etc.) must be on a stable dose for at least 4 weeks prior to starting study treatmentXx_NEWLINE_xXCurrently receiving statin therapy or have received any statin therapy within the last 3 monthsXx_NEWLINE_xXPatients who are currently receiving treatment with medications with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to study enrollmentXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) AND are unable to discontinue this medication or switch to a different medication prior to beginning study treatment are not eligible for participationXx_NEWLINE_xXPatients receiving other anti-neoplastic agents are excludedXx_NEWLINE_xXRefractory to ofatumumab (progression or relapse <12 months of receiving ofatumumab therapy or <24 months of receiving an ofatumumab- containing regimen)Xx_NEWLINE_xXSubject is currently being treated with anti-epileptics.Xx_NEWLINE_xXPatients may not be receiving or have received any other investigational agents during/or within 1 month prior to treatment with oregovomab or nelfinavirXx_NEWLINE_xXPatient is currently receiving any of the following medications and cannot be discontinued 7 days prior start if the treatment:Xx_NEWLINE_xXreceiving ibrutinib and progressing at the time of study enrollmentXx_NEWLINE_xXFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)Xx_NEWLINE_xXParticipants who are currently receiving enzyme-inducing anticonvulsantsXx_NEWLINE_xXPatients that have received the study medication (Xgeva/Prolia)Xx_NEWLINE_xXPatients currently receiving bone loss prevention treatment with bone-sparing agents must be on stable doses for at least 4 weeks prior to randomizationXx_NEWLINE_xXPatients receiving any concurrent immunosuppressantsXx_NEWLINE_xXPatients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) are ineligibleXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXParticipants may not be currently receiving any other experimental agentsXx_NEWLINE_xX-  INCLUSION CRITERIA:\n\n          -  Patients must have histologically confirmed hairy cell leukemia or hairy cell leukemia\n             variant .with a need for therapy\n\n          -  Patients must be Pseudomonas-immunotoxin naive\n\n          -  Patients must have had at least 2 prior purine analogs, or at least 1 course of purine\n             analog and 1 of either rituximub or BRAF inhibitor.\n\n          -  Men or women age greater than or equal to 18 years.\n\n          -  ECOG performance status less than or equal to 2.\n\n          -  Patients must have adequate organ function\n\n        EXCLUSION CRITERIA\n\n          -  Patients who have had chemotherapy, immunotherapy or radiotherapy within 4 weeks prior\n             to entering the study.\n\n          -  Patients who are receiving any other investigational agents.\n\n          -  Patients with known brain metastases should be excluded from this clinical trial\n\n          -  Patients with clinically significant ophthalmologic findings during screening\n\n          -  Pregnant or breastfeeding females.\n\n          -  Positive for Hepatitis B core antibody surface antigen unless the patient is on\n             Lamivudine or Entecavir and Hepatitis B Viral DNA load is less than 2000 IU/mL.\n\n          -  Lymph nodes greater than 4cm or prior splenectomy\n\n          -  Active second malignancy requiring treatment other than minor resection of indolent\n             cancers like basal cell and squamous skin cancers\n\n          -  HIV-positive patients unless taking appropriate anti-HIV medications with a CD4 count\n             of greater than 200.\n\n          -  History of allogeneic bone marrow transplant.\n\n          -  Patients with history of both thromboembolism and known congenital hypercoagulable\n             conditions.\n\n          -  Uncontrolled pulmonary infection, pulmonary edema.\n\n          -  Aequate oxygen saturation\n\n          -  Radioimmunotherapy within 2 years prior to enrollment in study.\n\n          -  Adequate hematologic function\n\n          -  Adequate lung function\n\n          -  Patients with history of thrombotic microangiopathy or TTP-HUS.\n\n          -  Patients with QTc interval (Federica) elevation > 500 msec based on at least 2\n             separate 12-lead ECGs\n\n          -  Patient on high dose estrogen\n\n          -  Patients with clinical evidence of disseminated intravascular coagulationXx_NEWLINE_xXPatient may not be receiving any other antineoplastic agents (hydroxyurea is allowed)Xx_NEWLINE_xXPatients may not be receiving Coumadin while on treatment; other anticoagulants are allowedXx_NEWLINE_xXPatients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatmentXx_NEWLINE_xXConcomitant medications\r\n* Patients receiving stable or decreasing corticosteroids are not eligible for other concurrent conditions (e.g. asthma, autoimmune diseases, rash, documented adrenal insufficiency) are eligible for this study\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXINR 0.8 to ULN or ? 3 for subjects receiving anticoagulant therapyXx_NEWLINE_xXPatients who are receiving concomitant D2-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registrationXx_NEWLINE_xXPatients that are currently taking any prohibitive medication; patients on therapeutic dose of warfarinXx_NEWLINE_xXNo patients receiving other investigational therapy for the past 30 days before dosing.Xx_NEWLINE_xXPatients currently receiving other investigational drugs are not eligibleXx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to study entry. (Please see www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm for a list of agents that prolong the QT interval.)Xx_NEWLINE_xXPatients must not have received any chemotherapy within 21 days of enrollment, and any acute treatment-related toxicities must have returned to baseline; patients may be receiving Hydrea at time of enrollmentXx_NEWLINE_xXAre currently taking insulinXx_NEWLINE_xXFor all patients:Xx_NEWLINE_xXPatients must not be receiving treatment for rheumatoid arthritis or systemic lupus erythematosusXx_NEWLINE_xXCurrently being treated with bronchodilators or corticosteroidsXx_NEWLINE_xXPatients receiving histone deacetylase (HDAC) inhibitors or compounds with HDAC inhibitor like activity, such as valproic acid, are ineligible; patients who have received such agents may enroll on this study after a 14-day washout periodXx_NEWLINE_xXSteroids: patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to baseline MRIXx_NEWLINE_xXPatients receiving whole brain radiation within 14 days prior to the first dose of study drugs will be excluded; NOTE: patients receiving palliative radiation (other than whole brain) before or during treatment may still be eligible as long as there are evaluable lesions that are not being irradiatedXx_NEWLINE_xXPatients receiving oral corticosteroids within 30 days of enrollment.Xx_NEWLINE_xXPatients who are currently receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with LGH447:Xx_NEWLINE_xXPatients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXFor Dose Confirmation (Parts B, D, E, F and G): Have CNS metastasis that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroidsXx_NEWLINE_xXFor Dose Confirmation (Part C): Have glioblastoma multiforme that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroidsXx_NEWLINE_xXIs currently participating in GSK1120212 study and is receiving treatment with GSK1120212.Xx_NEWLINE_xXReceiving concurrent endocrine, cytotoxic, or biologic agent(s) or within time limits specified above prior to study day 1Xx_NEWLINE_xXCurrently receiving treatment with medication known to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXReceiving, or planning to receive, any of the medications listed in the Prohibited Medications during conduct of the studyXx_NEWLINE_xXPatients with active infection requiring systemic therapy or who are dependent on or currently receiving antibiotics that cannot be discontinued before dosing; (Note: subjects who discontinue an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of antibiotic before receiving any ADXS11-001 infusion)Xx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval if that treatment cannot be either discontinued or switched to a different medication (not known to affect QT interval) prior to course 1 day 1 (C1D1)Xx_NEWLINE_xXPatients who are currently taking vitamin supplements including lycopene and beta-carotene are eligibleXx_NEWLINE_xXPatients who are currently taking Coumadin are not eligibleXx_NEWLINE_xXCurrently receiving treatment with any prohibited medication(s)Xx_NEWLINE_xXPatients must be at least 48 hours from placement of central catheter before receiving first dose of bevacizumabXx_NEWLINE_xXIf a patient has any serious medical problems which may preclude receiving this type of treatmentXx_NEWLINE_xXPatients who are currently participating or planning to participate in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study or who are receiving other investigational agents.Xx_NEWLINE_xXWomen currently on tamoxifen and raloxefene for prevention are not eligibleXx_NEWLINE_xXEligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity of pharmacokinetics (PK) of AZD2171 will be determined following review of their case by the principal investigator; efforts should be made to switch patients with brain metastases who are taking enzyme-inducing anticonvulsant agents to other medications one week prior to starting therapyXx_NEWLINE_xXPatients may not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, ibuprofen, pentamidine)Xx_NEWLINE_xXPatients receiving anti-hypertensive medicines must be on a stable regimen for at least 1 monthXx_NEWLINE_xXPatients who were receiving axitinib tablets at the time their previous trial endedXx_NEWLINE_xXPatients receiving anti-coagulation therapy are excludedXx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.Xx_NEWLINE_xXPatients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on study.Xx_NEWLINE_xXLaboratory values that would not prevent the patient from receiving chemotherapy as determined by the Principal Investigator (PI) or study oncologistXx_NEWLINE_xXSubjects currently receiving treatment with any medications that have the following potential properties and who cannot be either discontinued or switched to a different medication:Xx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval if that treatment cannot be either discontinued or switched to a different medication prior to administration of study drugXx_NEWLINE_xXCurrently receiving anti-cancer therapy. Exceptions: Zoledronic acid and denosumab to treat bone metastasis are allowed.Xx_NEWLINE_xXPatients will be excluded if they are receiving Valproic Acid (VPA) therapy.Xx_NEWLINE_xXSubject agrees not to participate in another interventional study while receiving study drug and participating in the present study.Xx_NEWLINE_xXReceiving other experimental therapyXx_NEWLINE_xXCurrently or previously treated with biologic, or immunotherapyXx_NEWLINE_xXReceiving medication that prolongs QT interval ,with a risk of causing Torsades de Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the medicationXx_NEWLINE_xXPatients receiving any disease-modifying anti-rheumatic drug (DMARD)Xx_NEWLINE_xXPatients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXProgressive disease while receiving a BTKi therapy, or stable disease as best response after 12 months of receiving a BTKi therapyXx_NEWLINE_xXRefractory to obinutuzumab (defined as progression or relapse <12 months of receiving obinutuzumab monotherapy or <24 months of receiving an obinutuzumab-containing regimen)Xx_NEWLINE_xXPatients receiving treatment with any medications that have the potential to prolong the QT interval who cannot discontinue such treatment or be switched to a different medication prior to starting study drug are excluded from the study entryXx_NEWLINE_xXPatient may not be receiving any other antineoplastic agentsXx_NEWLINE_xXCurrently receiving other anti-cancer agentsXx_NEWLINE_xXConcurrent anticoagulation will be permitted providing the patient is receiving a stable dose of anticoagulants before study entry; patients receiving anticoagulants will be eligible for this trial; evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g., INR > 1.5 without vitamin K antagonist therapy) will not be permittedXx_NEWLINE_xXPatients currently on other protease inhibitors; patients can be switched to an alternative combination antiretroviral therapy regimen, as deemed appropriate by their HIV care providerXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are excluded from this trialXx_NEWLINE_xXCurrently receiving warfarin or other coumadin-derived anticoagulants for treatment, prophylaxis or otherwise.Xx_NEWLINE_xXReceiving immunosuppressive drugsXx_NEWLINE_xXALL PATIENTS:Xx_NEWLINE_xXPatients who are receiving concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) (e.g., carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital and primidone) or who received EIAEDs within 2 weeks prior to the first dose of study drugXx_NEWLINE_xXPatients receiving full dose anticoagulative therapyXx_NEWLINE_xXPatients who are currently receiving treatment with warfarin sodium (Coumadin®) or any other coumarin-derivative anti-coagulantsXx_NEWLINE_xXPatients who are receiving any other investigational agents with the intent to treat myeloma; permitted concurrent therapies include:\r\n* BisphosphonatesXx_NEWLINE_xXIf a subject is receiving allopurinol/cimetidine/antivirals they must be discontinued prior to starting this protocolXx_NEWLINE_xXCurrently receiving treatment with therapeutic doses of warfarin sodium.Xx_NEWLINE_xXPatients currently receiving chemotherapy or radiation therapy.Xx_NEWLINE_xXThe participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.Xx_NEWLINE_xXHave a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs.Xx_NEWLINE_xXCurrently receiving vismodegib, biologics or chemotherapyXx_NEWLINE_xXPatients receiving (anti-thymocyte globulin) ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of treatment with Viralym-CXx_NEWLINE_xXSubjects who are currently receiving or have had previous hormonal, chemotherapy, or radiotherapy for prostate cancerXx_NEWLINE_xXPatients receiving steroids or immunosuppressive therapy for the improvement of hematological parameters (stable steroid treatment for adrenal failure or chronic medical conditions, and intermittent dexamethasone as antiemetics are allowed).Xx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligibleXx_NEWLINE_xXPatients who are currently receiving enzyme inducing anticonvulsants are not eligibleXx_NEWLINE_xXPatients with:Xx_NEWLINE_xXInstitutional normalized ratio (INR) =< 1.5 x ULN (this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)Xx_NEWLINE_xXActivated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)Xx_NEWLINE_xXCurrently receiving adjuvant trastuzumab (Herceptin)Xx_NEWLINE_xXPatients currently receiving any medication that has the potential to prolong the QT interval or induce Torsades de PointesXx_NEWLINE_xXSubjects receiving Coumadin anticoagulantsXx_NEWLINE_xXPatients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:Xx_NEWLINE_xXpatient was currently enrolled in Novartis sponsored study, which had met its endpoint and was receiving single agent oral dovitinib or dovitinib and fulvestrant coadministrationXx_NEWLINE_xXInclusion Criteria:\n\n        Cohort 0 and Arm A\n\n          -  Patient must have histologically or cytologically confirmed advanced cancer for which\n             standard cures or relieving measures either do not exist, are ineffective or are not\n             acceptable to the patient.\n\n          -  Measureable disease according to RECIST criteria version 1.1.\n\n          -  ECOG performance status of 0 to 1.\n\n          -  Adequate bone marrow function.\n\n        Arm B\n\n          -  Patients with documented acute myeloid leukemia (AML), except for acute promyelocytic\n             leukemia.\n\n          -  Patients with relapsed/refractory AML or patients who have not received prior therapy\n             who are high risk according to European LeukemiaNet (ELN) criteria.\n\n          -  ECOG performance status of 0 to 2.\n\n        For Cohort 0, Arms A and B\n\n          -  Life expectancy of >/= 12 weeks.\n\n          -  Age >/= 18 years or older.\n\n          -  All patients must be willing to use effective methods of contraception until 10 days\n             after the last dose; women must not be pregnant or breast-feeding.\n\n          -  Adequate renal and hepatic function.\n\n          -  Patients with stable central nervous system (CNS) tumors are eligible.\n\n          -  There are no requirements or limitations on the amount or type of prior\n             anti-tumor/anti-leukemia therapy.\n\n        Exclusion Criteria:\n\n        Cohort 0 and Arm A\n\n          -  Patients with a history of any form of leukemia except for Stage 0 and 1 chronic\n             lymphocytic leukemia (CLL) not requiring treatment.\n\n          -  Patients receiving any cancer treatment within 21 days of start of study medication.\n             Patients must also have recovered from severe side effects due to prior treatment\n             before study start.\n\n          -  Patients with known bone marrow disorders that may interfere with bone marrow\n             recovery, or patients with delayed recovery from prior chemoradiotherapy.\n\n          -  Patients with known bleeding or clotting disorders or non-drug-induced low platelet\n             count.\n\n        Arm B\n\n        - Patients receiving any cancer treatment within 14 days of start of study medication.\n        Hydroxyurea may be taken until first administration of the study drug. Patients must also\n        have recovered from severe side effects due to prior treatment before study start.\n\n        For Cohort 0, Arms A and B\n\n          -  Patients receiving any other test drugs within 30 days of start of study medication\n\n          -  Patients receiving the cytochrome P450 inhibitors, substrates or inducers specified in\n             the protocol.\n\n          -  Anticoagulation or antiplatelet treatment must be discontinued 7 days prior to start\n             of study medication.\n\n          -  Patients who have received hormonal therapy (except for prostate cancer treatment and\n             hormone replacement therapy) within the 2 weeks prior to start of study medication.\n\n          -  Patients with evidence of electrolyte imbalance, which may be treated to meet\n             eligibility.\n\n          -  Serum albumin < 2.8 g/dL.\n\n          -  HIV-positive patients who are currently receiving combination antiretroviral therapy.\n\n          -  Patients who have any severe and/or uncontrolled medical conditions or other\n             conditions that could affect their participation in the study.Xx_NEWLINE_xXPatients who are receiving drugs that prolong the QTc are not eligibleXx_NEWLINE_xXPatients who are receiving other cancer directed therapy at the time of enrollmentXx_NEWLINE_xXPatients receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); these medications must have been started >= month prior to enrollment on this study; patients may be on low molecular weight heparin or direct factor Xa inhibitorsXx_NEWLINE_xXPatients taking the following medications may experience QT/QTc interval prolongation and are not eligible for the trial - most anti-arrhythmia drugs (incl. amiodarone), erythromycin, quinolone antibiotics, ketoconazole, Zithromax, and phenothiazine and will be denied enrollment in the study. The possible interactions of these drugs and DM-CHOC-PEN have not been established. Patients receiving these drug will only be eligible if they discontinue the drugs and have an acceptable ECG.Xx_NEWLINE_xXSubjects who are not currently taking prohibited medicationXx_NEWLINE_xXIs currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acidXx_NEWLINE_xXPatients must agree to forgo any other treatments, including but not limited to cytotoxic or biologic chemotherapies, that are intended to treat the recurrent GBM while receiving treatment with NovoTTF therapyXx_NEWLINE_xXCurrently receiving any other investigational agents that are intended as treatments of recurrent GBMXx_NEWLINE_xXSubjects receiving any other investigational medicinal product or anti-cancer therapy.Xx_NEWLINE_xXPatients currently receiving active therapy for other neoplastic disordersXx_NEWLINE_xXPatient is currently receiving an enzyme-inducing anti-epileptic drug (EIAED). The patient must have discontinued EIAED therapy for at least two weeks prior to starting study drug.Xx_NEWLINE_xXIf receiving hydroxyurea or erythropoietin, treatment must have been prescribed for at least 6 months, with the dose stable for at least 3 monthsXx_NEWLINE_xXPART II: Currently receiving chemotherapy or radiation therapyXx_NEWLINE_xXPatients must not be receiving valproic acidXx_NEWLINE_xXPatients who are receiving or have received any other investigational agents within 30 days of study day 1, or who have previously received MK-2206 at any timeXx_NEWLINE_xXPatients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans.Xx_NEWLINE_xXPatients who are currently receiving treatment with agents that are metabolized predominantly through CYP3A4 and that have a narrow therapeutic window.Xx_NEWLINE_xXPatients receiving treatment with bupropion.Xx_NEWLINE_xXPatients currently receiving systemic corticosteroidsXx_NEWLINE_xXEligibility of patients receiving any medications or substances known to affect or with the potential to affect the androgen axis will be determined following review of their case by the principal investigatorXx_NEWLINE_xXPatients who are currently receiving active therapy for other neoplastic disorders will not be eligibleXx_NEWLINE_xXPatients who are receiving any androgens, estrogens or progestational agents, or who received any of these agents within the 6 months prior to evaluation will not be eligibleXx_NEWLINE_xXMust have been receiving or have received crizotinibXx_NEWLINE_xXPatients who are currently receiving lithium chloride (LiCl)Xx_NEWLINE_xXPatients with histologically confirmed diagnosis of MB, who have experienced relapse or progression after standard-of-care therapy including radiotherapy. Patients currently receiving steroids must have been on a stable (or decreasing) dose for at least 5 days before initiating study therapy.Xx_NEWLINE_xXPatients who have received prior treatment with cyclophosphamide and topotecan are eligible if they did not have tumor relapse/progression while receiving this combination.Xx_NEWLINE_xXPatients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.Xx_NEWLINE_xXPatients must not be receiving other investigational medications (covered under another IND) while on study.Xx_NEWLINE_xXPatients must not be receiving active anti-coagulation therapy at the time of study entry (or while on study).Xx_NEWLINE_xXPatients with cardiac arrhythmias must not be receiving anti-arrhythmic medication at time of study entry (or while on study).Xx_NEWLINE_xXPatients must not be receiving anti-hypertensive medications at time of study entry.Xx_NEWLINE_xXPatients who have recurrent hepatocellular carcinoma following hepatic transplantation are excluded unless the following criteria are met: i. Transplantation was performed at least 6 months prior to the relapse of HCC. ii. Patients are on stable immune suppressive therapy with no clinical evidence of rejection. iii. Are receiving ? 2.5 mg everolimus daily. d. Patients with known HIV infection are excluded. e. Patients with Hepatitis B are eligible provided there is no active viral replication. Patients with Hepatitis C who are not on interferon are eligible.Xx_NEWLINE_xXAny prohibited medication(s), currently used or expected to be required.Xx_NEWLINE_xXEligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of cabozantinib will be determined following review of their cases by the principal investigator; patients who are taking enzyme-inducing anticonvulsant agents are not eligibleXx_NEWLINE_xXIf a patient has any serious medical problems which may preclude receiving this type of treatmentXx_NEWLINE_xXSubjects currently receiving anti-cancer therapies (other than SSAs, which may continue).Xx_NEWLINE_xXMust not be receiving other anti-cancer therapies (except somatostatin analogues, which may be allowed)Xx_NEWLINE_xXContra-indications to receiving gadolinium contrastXx_NEWLINE_xXPatients already receiving metformin or anti-diabetic medications are INELIGIBLEXx_NEWLINE_xXPatient has evidence of progressive disease while receiving iniparib.Xx_NEWLINE_xXPatient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol.Xx_NEWLINE_xXPatients who are currently receiving active therapy for other neoplastic disorders will not be eligibleXx_NEWLINE_xXReceiving any medication that has documented data or is generally accepted as having increased risk of QT prolongation and/or Torsades de PointesXx_NEWLINE_xXPatient is currently receiving increasing or chronic treatment with corticosteroids or another immunosuppressive agentXx_NEWLINE_xXPatient is currently receiving an enzyme inducing anti-epileptic drug. The patient must have discontinued EIAED therapy for at least two weeks prior to starting study drug. Non-enzyme inducing anti-epileptic medication is allowed, except those listed in the protocolXx_NEWLINE_xXPatients must not have had disease progression while receiving siltuximab. For those patients originally assigned to placebo in the CNTO328MCD2001 study, patients who have received less than 4 months of siltuximab following crossover will also be eligibleXx_NEWLINE_xXPatients planning on receiving other anti-cancer therapies while on this studyXx_NEWLINE_xXPatients receiving corticosteroids aside from dexamethasone treatment directed at leukemiaXx_NEWLINE_xXPatients may not be receiving any agents not approved by the Food and Drug Administration (FDA) within the past 4 weeksXx_NEWLINE_xXPatients who are currently receiving treatment with QT prolonging medication with a known risk to induce Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients receiving herbal preparations/medicationsXx_NEWLINE_xXPatients who have a history of alcohol or drug abuse in the 6 month period prior to receiving treatment with pasireotide or RAD001Xx_NEWLINE_xXif receiving corticosteroids, dose is stable or decreasing for past 7 daysXx_NEWLINE_xXPatients taking medications known to cause prolongation of the QT interval and associated with torsades de points; patients receiving drugs that are “possibly” or have a “conditional” risk may be enteredXx_NEWLINE_xXpatients receiving therapy with any medications with a known risk or possible risk to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.Xx_NEWLINE_xXpatients receiving hydroxyurea or corticosteroids that has not been discontinued at least 1 week after initiation of nilotinibXx_NEWLINE_xXThe patient is receiving full dose subcutaneous heparins or is under anti-coagulation treatment.Xx_NEWLINE_xXActive diagnosis of psoriasis or currently receiving treatment for psoriasis.Xx_NEWLINE_xXCurrently receiving treatment with any medications listed on the prohibited medication listed in the protocolXx_NEWLINE_xXThe participant is receiving depot octreotide therapy at the time of enrolling into the studyXx_NEWLINE_xXAll patients must:Xx_NEWLINE_xXCurrently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization)Xx_NEWLINE_xXPatients who are currently taking immunosuppressive medicationsXx_NEWLINE_xXCurrently enrolled in another interventional studyXx_NEWLINE_xXPatients may not be receiving any medications that are known to prolong QT interval unless reviewed and approved by the principal investigator (PI)Xx_NEWLINE_xXFemale patients must agree (during the study and for 3 months after receiving the last dose of study agent, not to donate eggs (ova, oocytes) for the purposes of assisted reproductionXx_NEWLINE_xXPatients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently receiving other anti-cancer agents are not eligible except for hydroxyurea (which may be continued until 24 hours prior to start of protocol therapy)Xx_NEWLINE_xXCurrently receiving treatment with any medication that has the potential to prolong the QT interval and the treatment cannot be discontinued or switched to a different medicationXx_NEWLINE_xXKnown history of QT/QTc prolongation or torsades de pointes (TdP); patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugsXx_NEWLINE_xXReceiving renal replacement therapy, hemodialysis, or peritoneal dialysisXx_NEWLINE_xXPatients may not be receiving any other drugs for the treatment of GvHD or investigational agents, except for a maximum of 48 hours of prior GC therapy, as above (obviously, this requirement is waived for SA – acute GvHD patients; in this case, no requirements are mandated)Xx_NEWLINE_xXReceiving any medications that prolong the corrected QT (QTc) and have a known risk for Torsades de pointes; note: providers should use caution with drugs with possible increased risk for Torsades de pointes; patient will be eligible if they can be taken off these medications prior to initiation of therapy and no less than 4 half-life of the medicationXx_NEWLINE_xXCurrently receiving any other investigational medication or therapyXx_NEWLINE_xXPatient is currently receiving or has received within the last month prior to Cycle 1 Day 1 (6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin) other chemotherapeutic, hormonal, or investigational anti-cancer agents with the exception of gonadal suppression agents and bisphosphonates for osteoporosis and skeletal metastases which may be continued while on studyXx_NEWLINE_xXNOTE: patients currently receiving warfarin must have approval from an oncologist or their designee to participate in this studyXx_NEWLINE_xXBe receiving quinolone antibiotic therapyXx_NEWLINE_xXPatients must not be currently taking or planning to take during study treatment the following medications:\r\n* B2 agonists\r\n* Bosutinib\r\n* Ceritinib\r\n* Floctafenine\r\n* Methacholine\r\n* Pazopanib\r\n* Rivastigmine\r\n* Vincristine\r\n* SilodosinXx_NEWLINE_xXPatients must not be registered to step 2 until receiving confirmation from the ECHO Core Lab that the patient’s LVEF by echocardiogram was >= 50% by central review; patients must be registered within 5 calendar days of receiving the e-mail notificationXx_NEWLINE_xXPATIENT: Receiving primary cancer care at one of the participating sitesXx_NEWLINE_xXPATIENT: They are already receiving PC or hospice servicesXx_NEWLINE_xXFor stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive diseaseXx_NEWLINE_xXCurrently already enrolled on the TrueNTH websiteXx_NEWLINE_xXPatients receiving chronic treatment with oral steroids or another immunosuppressive agent (excluding steroids as part of the chemotherapy pre-medication or emetic medication)Xx_NEWLINE_xXPHASE I: Currently taking AETXx_NEWLINE_xXPatient's household is currently receiving or applying for Supplemental Nutrition Assistance Program (SNAP) benefits (formerly known as food stamps)Xx_NEWLINE_xXPatients already receiving palliative careXx_NEWLINE_xXPatients receiving non-intensive treatmentXx_NEWLINE_xXPatient is currently enrolled in hospiceXx_NEWLINE_xXPatients who eitherXx_NEWLINE_xXCurrently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.Xx_NEWLINE_xXPatients who are currently receiving physical therapy or practicing yoga for any reasonXx_NEWLINE_xXCurrently receiving palliative or hospice careXx_NEWLINE_xXCurrently receiving reflexology or meditative practicesXx_NEWLINE_xXAre receiving chronic oxygen therapyXx_NEWLINE_xXPatient receiving anticoagulationXx_NEWLINE_xXPatient receiving antiplatelet agentsXx_NEWLINE_xXimmunodeficiency, immune compromised state or receiving immunosuppressive therapyXx_NEWLINE_xXSubject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.Xx_NEWLINE_xXSubject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.Xx_NEWLINE_xXInfection requiring receipt of therapeutic oral or IV anti-microbials within 2 weeks of first study treatment; patients receiving routine anti-microbial prophylaxis (for dental extractions/procedures) are eligibleXx_NEWLINE_xXThey are already receiving PC or hospice servicesXx_NEWLINE_xXPatients currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin (Neurontin) or pregabalin (Lyrica) will be tapered off these medications over 7 days; the study team will provide instructions on how to do thisXx_NEWLINE_xXPatients not receiving care at Massachusetts General Hospital (MGH)Xx_NEWLINE_xXPatients receiving intensive chemotherapy requiring a prolonged 4-6 week hospitalizationXx_NEWLINE_xXPatients receiving supportive care aloneXx_NEWLINE_xXPatients already receiving palliative careXx_NEWLINE_xXSubjects currently receiving hemodialysisXx_NEWLINE_xXAdult patients with a cancer diagnosis receiving oral or intravenous (IV) chemotherapy at Dana-Farber on Yawkey 10Xx_NEWLINE_xXPatients with galactosemiaXx_NEWLINE_xXPatients currently taking anabolic steroids will be excluded; patients taking corticosteroids are allowed on studyXx_NEWLINE_xXCurrently receiving hospice care (patients who enroll in hospice during the trial will have the option of continuing trial participation)Xx_NEWLINE_xXPatients with currently uncontrolled cardiac arrhythmias (non-sinus rhythm) will be excluded; patients with history of arrhythmias under pharmacological/pacemaker control will be allowed, except if receiving antiarrhythmic medication listed in “contra-indicated medications” belowXx_NEWLINE_xXPatients may not be receiving any other investigational agents.\r\n* Note: it is acceptable to be on combination therapy including either sorafenib, regorafenib, and/or sunitinib.Xx_NEWLINE_xXIn remission at time of study entry, may be receiving chemopreventionXx_NEWLINE_xXPATIENTSXx_NEWLINE_xXPatients who are receiving therapy with an anthracyclineXx_NEWLINE_xXPATIENTS: Patients with hematologic cancer receiving care at a participating clinic.Xx_NEWLINE_xXPatients who are receiving neoadjuvant chemotherapy treatment at University of Texas (UT) MD Anderson Cancer CenterXx_NEWLINE_xXCurrently receiving home delivered meals from other sourcesXx_NEWLINE_xXPatient receiving active intravenous, intraperitoneal or oral chemotherapyXx_NEWLINE_xXPatients not receiving intravenous, intraperitoneal or oral chemotherapy at the time of enrollmentXx_NEWLINE_xXCurrently receiving acupuncture for any condition or if they have ever used acupuncture beforeXx_NEWLINE_xXSubjects not receiving clinical benefit from previous study therapyXx_NEWLINE_xXPatient is taking medications or supplements for weight loss currently or within the past 3 monthsXx_NEWLINE_xXThe patient sample is limited to patients with advanced cancer and/or patients receiving ongoing care from a medical oncologistXx_NEWLINE_xXPATIENTS ONLY: Currently receiving treatment (e.g. radiotherapy, chemotherapy) at MD Anderson Cancer CenterXx_NEWLINE_xXWomen who are receiving endocrine therapy at the time of recruitment are eligible for the studyXx_NEWLINE_xXCurrent thromboembolic disease requiring full-dose anticoagulation patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligibleXx_NEWLINE_xXCurrently on gabapentinXx_NEWLINE_xXPatients receiving 3rd-line palliative chemotherapyXx_NEWLINE_xXReceiving a G-CSF after the institution practice changeXx_NEWLINE_xXMay be concurrently receiving endocrine or HER2 directed therapyXx_NEWLINE_xXReceiving erythropoietin stimulating agents prior to admissionXx_NEWLINE_xXPatients receiving preoperative enteral nutritionXx_NEWLINE_xXSubjects currently participating in a RT programXx_NEWLINE_xXPediatric oncology patients undergoing a lumbar puncture in the Pediatric Sedation Suite; patients may or may not be receiving intrathecal chemotherapyXx_NEWLINE_xXAre receiving active treatment (e.g., radiation, hormone, or chemotherapy) or have been receiving treatment in the past 6 months for prostate, breast, lung, lymphoma, or gynecological cancerXx_NEWLINE_xXPatients actively receiving radiation to the head, neck, or gastrointestinal tractXx_NEWLINE_xXSubjects are currently receiving ADT for prostate cancer and will continue on ADT for at least 13 weeks after enrollment. Patient may have been started on ADT at any past time point because patients experience hot flashes throughout ADT treatment.Xx_NEWLINE_xXSubjects already receiving other treatment for hot flashes.Xx_NEWLINE_xXPatients who are classified as being opioid tolerant by receiving a baseline MEDD of >= 60 mgXx_NEWLINE_xXPatients receiving scheduled benzodiazepines due to the risk of excessive sedationXx_NEWLINE_xXPatients who are deliriousXx_NEWLINE_xXPatients receiving myeloablation (MA) or reduced intensity conditioning (RIC) are allowedXx_NEWLINE_xXPATIENTS: Find conversations around religion or spirituality emotionally upsettingXx_NEWLINE_xXPHASE I AIM 1: Receiving any type of cancer treatmentXx_NEWLINE_xXPHASE I AIM 3.1: Receiving any type of cancer treatmentXx_NEWLINE_xXPHASE II AIM 2: Receiving any type of cancer treatmentXx_NEWLINE_xXPatients receiving treatment for an IFI are not eligibleXx_NEWLINE_xXCurrently receiving rehabilitationXx_NEWLINE_xXAt the time of recruitment the patient is on active treatment defined as either currently receiving chemotherapy or radiation or less than 6 months post-cancer surgeryXx_NEWLINE_xXPatients currently enrolled on Children's Oncology Group (COG) study ACCL0934 are not eligible until they have completed the infection observation period of that studyXx_NEWLINE_xXPatients receiving sorafenib at the time of enrollment and those who are scheduled to receive sorafenib as part of a treatment plan are ineligibleXx_NEWLINE_xXPatients receiving treatment for an IFI are not eligibleXx_NEWLINE_xXPatients currently enrolled on the ACCL1034 study are not eligible until they have completed the 90 day observation period of that studyXx_NEWLINE_xXCurrently receiving gabapentin or pregabalin and not willing to be weaned off of these medications prior to Scrambler therapy initiation\r\n* Note: it is OK to continue these medications in patients who are receiving TENSXx_NEWLINE_xXCurrently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin [Neurontin] or pregabalin [Lyrica]); all patients on these medications will be weaned off them prior to study initiationXx_NEWLINE_xXCurrently receiving other alternative treatment for CDI (e.g. antibiotics other than metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)Xx_NEWLINE_xXThey are already receiving PC or hospice servicesXx_NEWLINE_xXPatients with history of lung disease currently requiring any supplemental oxygen treatmentXx_NEWLINE_xXPatients currently using a wearable activity trackerXx_NEWLINE_xXCurrently enrolled in a physical therapy courseXx_NEWLINE_xXCurrently participating in couple/marital therapyXx_NEWLINE_xXThose receiving alternate regimens and those with other disease typesXx_NEWLINE_xXReceiving or planning to receive outpatient therapy for any cancerXx_NEWLINE_xXPATIENT: Be receiving care from a medical oncologist enrolled in the studyXx_NEWLINE_xXPATIENT: Currently receiving hospice careXx_NEWLINE_xXINTERVENTION PHASE: Currently receiving acupuncture treatment for CIPNXx_NEWLINE_xXPatients who are currently receiving acupuncture for any condition or if they have ever had acupuncture beforeXx_NEWLINE_xXCANCER PATIENT GROUP: Currently receiving ADT treatment for at least 6 months (and continue to receive treatment during the duration of the study)Xx_NEWLINE_xXMay be receiving maintenance therapy that has a goal of prevention of recurrence but there should be no expectations for further active treatmentXx_NEWLINE_xXCurrently on hospice careXx_NEWLINE_xXCurrently receiving other intravesical chemotherapy.Xx_NEWLINE_xXDose Confirmation Cohort A (DC-A) only: Currently receiving enzalutamide as most recent systemic therapy for mCRPC and have experienced PSA progression by PCWG2 criteria in the absence of radiographic and/or clinical progression. Patients may or may not have experienced prior progression on abiraterone.Xx_NEWLINE_xXPatients with history of liver transplantation may be eligible for the dose expansion cohorts (parts 2A and 2B) of this study provided all eligibility criteria are met and provided the subject has not had any episodes of acute rejection or serious opportunistic infection within 3 months from enrollment\r\n* Certain immunosuppressive agents such as tacrolimus and sirolimus are prohibited thus liver transplant patients who require these medications for immunosuppression are not eligible\r\n* Patients receiving everolimus at immunosuppressive dosages are eligibleXx_NEWLINE_xXPatients receiving concurrent additional biologic therapyXx_NEWLINE_xXPatient may be receiving bone targeted agentsXx_NEWLINE_xXCurrently receiving anticoagulation treatmentXx_NEWLINE_xXPatients with SCNSL actively receiving treatment for extra-CNS disease are excludedXx_NEWLINE_xXCurrently receiving Dilantin (phenytoin) or auranofin or another gold-containing compoundXx_NEWLINE_xXCurrently receiving immune-modulating therapiesXx_NEWLINE_xXPatients: Receiving an allogeneic HSCTXx_NEWLINE_xXPatient is receiving hospice careXx_NEWLINE_xXPatients currently receiving therapy for mucositisXx_NEWLINE_xXPATIENTS:Xx_NEWLINE_xXPATIENTSXx_NEWLINE_xXOngoing parenteral nutrition (receiving intravenous nutrition support at the time of enrollment); note: patients may be receiving maintenance intravenous (IV) fluidsXx_NEWLINE_xXPatients who currently have no evidence of diseaseXx_NEWLINE_xXPatients receiving chemotherapy at the University of Wisconsin-MadisonXx_NEWLINE_xXPatients receiving other investigational drugs for GVHD; co-enrollment in other clinical trials that do not include experimental GVHD therapies is allowedXx_NEWLINE_xXReceiving hospice careXx_NEWLINE_xXCancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), orXx_NEWLINE_xXParticipant currently is taking melatoninXx_NEWLINE_xXParticipant is currently receiving treatment with fluvoxamineXx_NEWLINE_xXParticipant is currently receiving treatment with anticoagulants (e.g. Coumadin)Xx_NEWLINE_xXParticipant is currently receiving treatment with immunosuppressants or corticosteroidsXx_NEWLINE_xXParticipant is currently receiving treatment with nifedipine (Procardia XL)Xx_NEWLINE_xXCurrently receiving anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, clonidine, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)Xx_NEWLINE_xXPatients with hemoglobin levels more than or equal to 8 g/dl would be eligible for the study even if they are currently receiving blood productsXx_NEWLINE_xXCML patients in chronic phase receiving treatment with any Food and Drug Administration (FDA) approved TKI; or CML patients in accelerated or blastic phase who are considered to be in this phase because of thrombocytopenia or because of clonal evolution and with no other criteria for accelerated/blastic phase or patients with myelofibrosis receiving treatment with FDA approved TKI and with peripheral blood and/or bone marrow blasts =< 10%Xx_NEWLINE_xXBe currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)Xx_NEWLINE_xXCurrently receiving phenobarbital, diphenylhydantoin, primidone, phenylbutazone, monoamine oxidase inhibitors (MAOIs), clonidine and tricyclic antidepressant drugsXx_NEWLINE_xXPlan to receive or is receiving primary frontline anti-myeloma therapiesXx_NEWLINE_xXPatients who are currently receiving acupuncture for any condition or if they have ever had acupuncture beforeXx_NEWLINE_xXReceiving erythropoietin stimulating agentXx_NEWLINE_xXPatients currently receiving or scheduled to receive a chemotherapy infusion other than adriamycin/cyclophosphamide prior to initiation of the metformin adaptation phase are not eligible; patients who are receiving adriamycin/cyclophosphamide must be scheduled to be at least 8 days post-chemotherapy infusion prior to initiation of the metformin adaptation phase in order to be eligibleXx_NEWLINE_xXPatients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)Xx_NEWLINE_xXAny woman currently pregnant will not be eligible, but may participate 3 or more\n             months after the end of her pregnancy if the study is still ongoingXx_NEWLINE_xXReceiving hormonal treatmentXx_NEWLINE_xXPatients currently taking valproic acidXx_NEWLINE_xXPatients must have neuropathy greater or equal to 2 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 scale, clinically evaluated within 30 days of consent, despite previous treatment, which may include Neurontin, Cymbalta and/or Lyrica for at least 30 days; patients receiving any of these drugs must remain on the same medications throughout the study period; however, adjustments in dosage are allowed; patients are allowed to stop medications but not replace them with other medicationsXx_NEWLINE_xXKnown contraindication to receiving G-CSFXx_NEWLINE_xXReceiving any agent concurrently with CLT-008 infusion which inhibits cell division (e.g., methotrexate or hydroxyurea)Xx_NEWLINE_xXPatients who do not have at least 10 weeks before receiving local controlXx_NEWLINE_xXCurrently receiving chemotherapy or radiationXx_NEWLINE_xXCurrently taking anti-hypertensive medicationsXx_NEWLINE_xXReceiving any agent classified as an antioxidantXx_NEWLINE_xXCurrently 2-10 years after first HCTXx_NEWLINE_xXPatients receiving anti-thymocyte globulin (ATG), or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollmentXx_NEWLINE_xXPatients receiving calcineurin inhibitors as part of GVHD prophylaxisXx_NEWLINE_xXSubjects who will be receiving dasatinibXx_NEWLINE_xXCurrently receiving chemotherapyXx_NEWLINE_xXPatients must have neuropathy greater or equal to 2 according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 scale despite previous treatment, which may include Neurontin, Cymbalta and/or Lyrica; patients receiving any of these drugs must remain on the same medications throughout the study period; however, adjustments in dosage are allowed; patients will be removed from the study if a change in type of medication is necessary; patients are allowed to stop medications but not replace them with other medicationsXx_NEWLINE_xXPATIENTS WITH BRONJ:Xx_NEWLINE_xXPATIENTS WITHOUT BRONJ:Xx_NEWLINE_xXGENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications\r\n* Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol \r\n* Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol \r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligibleXx_NEWLINE_xXPatientsXx_NEWLINE_xXCurrently receiving tamoxifen or raloxifeneXx_NEWLINE_xXReceiving pyrimethamine, cimetidine, rifampin or cephalexinXx_NEWLINE_xXPatient is receiving or plans to receive other investigational therapy during study.Xx_NEWLINE_xXCurrently receiving anticoagulant therapyXx_NEWLINE_xXAnti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from hematological and bone marrow suppression effects of prior chemotherapy.Xx_NEWLINE_xXHistory of receiving 2017-2018 influenza vaccineXx_NEWLINE_xXCurrently receiving therapeutic anticoagulant therapy or dual antiplatelet therapy (e.g. aspirin and clopidogrel)Xx_NEWLINE_xXPatients already on AED(s)Xx_NEWLINE_xXCurrently taking psychotropic or cardiovascular medicationXx_NEWLINE_xXCurrently taking psychotropic or cardiovascular medicationXx_NEWLINE_xXPatients must be receiving cisplatin therapy for a non-head and neck malignancy in total doses >= 100 mg/m^2Xx_NEWLINE_xXCurrently taking medication that may impact weight (e.g., Synthroid, metformin)Xx_NEWLINE_xXWomen who are receiving any other concomitant treatment for their DCIS/ADHXx_NEWLINE_xXPatients with any of the following are not eligible:Xx_NEWLINE_xXNot currently taking aspirin (any dose) within the last 6 monthsXx_NEWLINE_xXPILOTS II and III: Currently receiving radiation therapy or cytotoxic chemotherapyXx_NEWLINE_xXCurrently enrolled at Salish Kootenai CollegeXx_NEWLINE_xXSUBJECTS ENROLLED IN THE TREATMENT GROUPS RECEIVING VACCINE ONLY (NOT THE IMIQUIMOD GROUP):Xx_NEWLINE_xXReceiving chemotherapy known to cause alopecia within 60 days of study or during the study.Xx_NEWLINE_xXCurrently in remission and not on any active anti-cancer therapies (survivors receiving maintenance tyrosine kinase inhibitors are NOT eligible).Xx_NEWLINE_xXPresence of at least 1 CV risk factor:\r\n* Currently on medication for hypertension, or\r\n* Currently on medication for cholesterol or triglyceride, or\r\n* Currently on medication for diabetes, or\r\n* Currently not physically active (self-reported average < 20 minutes/day), or\r\n* Currently smoking.Xx_NEWLINE_xXCurrently institutionalizedXx_NEWLINE_xXReceiving maintenance therapy with mesalamine for at least 3 monthsXx_NEWLINE_xXWomen receiving a “nipple delay” procedure prior to mastectomyXx_NEWLINE_xXCurrently taking spironolactoneXx_NEWLINE_xXPlan to initiate systemic cancer therapy within plus or minus (+-) 1 week of receiving the first dose of study drug with the intention of receiving systemic cancer therapy during the double-blind treatment period for an intended duration determined by the treating oncologist according to standard protocols of clinical careXx_NEWLINE_xXIs receiving any prohibited drugsXx_NEWLINE_xXCurrently non-active (exercise two days or less per week)Xx_NEWLINE_xXNot currently using immunosuppressant medicationsXx_NEWLINE_xXCurrently receiving or has received any investigational drugs within the 14 days prior to the first dose of the conditioning regimenXx_NEWLINE_xXIndividual may not be receiving any other investigational agents, antiplatelet agents (e.g. aspirin, clopidogrel [Plavix or others]), anticoagulants (e.g. heparin or heparinoids, Coumadin, or others), methotrexate, lithiumXx_NEWLINE_xXCurrently receiving vismodegib, biologics or chemotherapyXx_NEWLINE_xXReceiving hormone replacement therapy that cannot be discontinuedXx_NEWLINE_xXEligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or PK of romidepsin will be determined following review of their case by the site principal investigator\r\n* Patients treated with any of the medications prohibited must discontinue their use at least 7 days prior to the first dose of romidepsin; certain other agents that interact with the CYP3A4 system may be used with cautionXx_NEWLINE_xXCurrently receiving or planning to receive other xerostomia treatment, including drugs, herbs or devices; all other treatments known to affect salivation should be stopped at least 14 days prior to enrollmentXx_NEWLINE_xXAnti-cancer Agents: Patients who are currently receiving other anticancer agents are not eligible. Patients must have fully recovered from the effects of prior chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas).Xx_NEWLINE_xXFor patients receiving therapeutic anticoagulation: stable anticoagulant regimenXx_NEWLINE_xXInclusion Criteria:\n\n        Diagnosis and Criteria for Inclusion:\n\n        All patients:\n\n        To be considered eligible to participate in this study, all of the following requirements\n        must be met:\n\n          1. Patient, male or female, is at least 18 years of age.\n\n          2. Patient has a diagnosis of advanced solid malignancy that has failed standard therapy\n             or for which standard therapy is not likely to provide meaningful benefit, or patient\n             has refused standard therapy.\n\n          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          4. Patient is able to take oral medications.\n\n          5. Female patient, if of childbearing potential, has a negative serum pregnancy test\n             within 72 hours prior to taking study drug and agrees to abstain from activities that\n             could result in pregnancy from enrollment through 120 days after the last dose of\n             study treatment, or be of non-childbearing potential. Non-childbearing potential is\n             defined as (by other than medical reasons):\n\n               -  ?45 years of age and has not had menses for > 1 year.\n\n               -  Amenorrheic for < 2 years without a hysterectomy Post hysterectomy, bilateral\n                  oophorectomy, or tubal ligation..\n\n             Note: Abstinence is acceptable if this is the established and preferred contraception\n             for the patient.\n\n          6. Male patient agrees to use an adequate method of contraception starting with the first\n             dose of study treatment through 120 days after the last dose of study treatment..\n\n          7. Patient is able to understand the study procedures and agrees to participate in the\n             study by providing written informed consent.\n\n        Patients with normal hepatic function (Group 1):\n\n        Patients screened for the normal hepatic function group must meet the following additional\n        criteria to be eligible for enrollment:\n\n          1. Patient has no history of hepatic impairment.\n\n          2. Patient has liver function test (LFT) results within normal range:\n\n               -  Total bilirubin ? ULN\n\n               -  Aspartate aminotransferase (AST) ? ULN.\n\n               -  INR ?1.5 X ULN unless the patient is receiving anticoagulant therapy and the INR\n                  is within therapeutic range of intended use of anticoagulants.\n\n          3. Patient has adequate hematologic and renal function as defined below:\n\n               -  Absolute neutrophil count ?1500/µL\n\n               -  Platelets ?100,000/µL\n\n               -  Hemoglobin ?9 g/dL\n\n               -  Serum creatinine ?1.5 × ULN or a calculated creatinine clearance ?60 mL/min using\n                  the Cockcroft-Gault equation.\n\n        Patients with moderate hepatic impairment (Group 2):\n\n        Patients screened for the moderate hepatic impairment group must meet the following\n        additional criteria to be eligible for enrollment:\n\n          1. Patient has stable, moderate hepatic impairment, defined as:\n\n               -  BILI: >1.5 × to 3 × ULN, for at least 2 weeks prior to Day 1\n\n               -  AST: Any value\n\n               -  INR less than 1.8 unless the patient is receiving anticoagulant therapy and the\n                  INR is within therapeutic range of intended use of anticoagulants.\n\n          2. Patient has hematologic and renal function as defined below:\n\n               -  Absolute neutrophil count ?1000/µL\n\n               -  Platelets ?75,000/µL\n\n               -  Hemoglobin ?8 g/dL\n\n               -  Serum creatinine ?1.5 × ULN or a calculated creatinine clearance ?60 mL/min using\n                  the Cockcroft-Gault equation.\n\n          3. Patient's hepatic disease is deemed stable by the Investigator\n\n        Criteria for Exclusion:\n\n        Patients will not be eligible for study entry if any of the following criteria are met:\n\n        All patients:\n\n          1. Patient has undergone palliative radiotherapy within 1 week of study drug\n             administration, encompassing >20% of the bone marrow.\n\n          2. Patient is starting chemotherapy within 3 weeks of study drug administration.\n\n          3. Patient has a known hypersensitivity to the components of niraparib or excipients\n\n          4. Patients who received colony-stimulating factors within 2 weeks prior to the first\n             dose of study treatment are not eligible.\n\n          5. Patient has persistent chemotherapy associated Grade 2 or greater toxicity except for\n             neuropathy, alopecia or fatigue.\n\n          6. Patient has symptomatic uncontrolled brain or leptomeningeal metastases.\n\n          7. Patient has undergone major surgery within 3 weeks of starting the study or patient\n             has not recovered from any effects of any major surgery.\n\n          8. Patient is considered a poor medical risk due to a serious, uncontrolled medical\n             disorder (other than hepatic impairment) or active, uncontrolled infection.\n\n          9. Patient has received a transfusion (platelets or red blood cells) within 3 weeks of\n             receiving niraparib.\n\n         10. Patient is pregnant, breastfeeding, or expecting to conceive children while receiving\n             study treatment or for 3 months after the last dose of study treatment.\n\n         11. Patient has a known history of myelodysplastic syndrome (MDS) or acute myeloid\n             leukemia (AML).\n\n             NOTE: Exclusion Criteria 12-16 apply patients participating in the PK phase of the\n             study.\n\n         12. Patient is currently receiving, or unable to refrain from taking from 4 days prior to\n             dosing until the time of the last PK blood draw, any of the following cytochrome (CYP)\n             1A2 substrates: alosetron, duloxetine, melatonin, ramelteon, tacrine, tizanidine, and\n             theophylline.\n\n         13. Patient is unable to refrain from any intake of grapefruit or grapefruit juice within\n             4 days of the first administration of niraparib until the final PK sample collection.\n\n         14. Patient is currently receiving, or unable to refrain from taking from 4 days prior to\n             dosing until the last PK blood draw, any of the following P-glycoprotein (P-gp)\n             inhibitors: amiodarone, azithromycin, captopril, carvedilol, clarithromycin,\n             conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine,\n             itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine,\n             ticagrelor and verapamil.\n\n         15. Patient is taking proton pump inhibitors, antacids, or histamine 2 (H2) blockers\n             within 48 hours prior to niraparib administration, and/or within 6 hours after\n             niraparib administration.\n\n         16. Patient has esophagogastrointestinal disease or resection that is likely to interfere\n             with the absorption of niraparib.\n\n        Patients with moderate hepatic impairment (Group 2):\n\n        Patients screened for the moderate hepatic impairment group who meet any of the following\n        additional criteria will be excluded from the study:\n\n          1. Patient has hepatic encephalopathy, severe portal hypertension and/or porto-systemic\n             shunt.\n\n          2. Patient has fluctuating or rapidly deteriorating hepatic function as determined by the\n             investigator within the screening period.\n\n          3. Patient has acute liver disease caused by drug toxicity or by an infection.\n\n          4. Patient has biliary obstruction or other causes of hepatic impairment not related to\n             parenchymal disorder and/or disease of the liver.\n\n          5. Patient has esophageal variceal bleeding within the past 2 months.\n\n          6. Patient is receiving anticoagulant therapy with warfarin or related coumarins.\n\n          7. Patient has a history of hepatic transplant, systemic lupus erythematosus, or hepatic\n             coma.Xx_NEWLINE_xXReceipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment; subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligibleXx_NEWLINE_xXCurrently receiving treatment for any malignancyXx_NEWLINE_xXReceiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexateXx_NEWLINE_xXSubject is receiving sodium-thiosulfate or amifostine therapy with chemotherapy.Xx_NEWLINE_xXPatients receiving phosphodiesterase type 5 (PDE-5) inhibitors (such as sildenafil, tadalafil, vardenafil)Xx_NEWLINE_xXPreviously diagnosed of ALL and currently in remissionXx_NEWLINE_xXPatients who currently have stomatitis/oral mucositis/mouth ulcers;Xx_NEWLINE_xXCurrently receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexateXx_NEWLINE_xXPatients receiving thiazides or furosemide diuretics, with the exception of subjects who have stable doses and have been on therapy for over six monthsXx_NEWLINE_xXSubject is currently receiving anticoagulation therapy other than acetylsalicylic acidXx_NEWLINE_xXcurrently minimally active,Xx_NEWLINE_xXPatients receiving NAC and having a nodal complete clinical response as assessed by physical examXx_NEWLINE_xXNot currently receiving cancer-directed therapyXx_NEWLINE_xXHemosiderosis/hemochromatosis (patients can still be included in the 2nd branch without receiving ferumoxytol)Xx_NEWLINE_xXCurrently receiving immunotherapyXx_NEWLINE_xXPreviously or currently receiving taxane-based chemotherapyXx_NEWLINE_xXPatients with esophageal cancer receiving trastuzamabXx_NEWLINE_xXCurrently receiving or history of systemic therapy with testosterone suppressing medication (i.e., lupron, degarelix, abiraterone, enzalutamide) or local radiation therapy.Xx_NEWLINE_xXPatients receiving T cell depletion or thymoglobulin as part of their transplantXx_NEWLINE_xXCurrently taking Glucophage or Glucovance (metformin)Xx_NEWLINE_xXHistory or currently taking immunosuppressionXx_NEWLINE_xXNot currently on ADTXx_NEWLINE_xXPatients with a known or suspected malignancy who are receiving care from a pediatric oncologist and are already scheduled to receive an outpatient PET/CT examinationXx_NEWLINE_xXReceiving a stable dose of octreotide LAR as a part of a treatment regimen for >= 3 monthsXx_NEWLINE_xXPatients receiving testosterone supplementationXx_NEWLINE_xXPatients currently receiving trastuzumab therapy with or without other types of systemic therapy can participate if their disease progresses (development of new lesion[s] or worsening of known lesion(s) based on imaging modalities or physical examinationXx_NEWLINE_xXPatients receiving corticosteroids are eligible provided the dose is stable or decreasing for at least 7 daysXx_NEWLINE_xXPatient must not be receiving any other anti-cancer agentXx_NEWLINE_xXIs currently receiving and able to discontinue erlotinib, gefinitib, afatinib, or osimertinibXx_NEWLINE_xXPatients must not currently be using other anti-cancer agentXx_NEWLINE_xXAll patients who have gynecologic malignancies involving the middle third and the distal third of the vagina who will be receiving radiation therapyXx_NEWLINE_xXReceiving care in the Breast Surgery Department at ColumbiaXx_NEWLINE_xXSubjects must be scheduled to begin treatment through the Vanderbilt-Ingram Cancer Center (VICC) Melanoma Program; this will include patients receiving standard-of-care chemotherapy, targeted therapy, and/or immunotherapy, as well as patients accrued to VICC clinical trials for the study of investigational agentsXx_NEWLINE_xXPatients receiving < 45 Gy radiationXx_NEWLINE_xXSubjects may not be receiving any experimental therapiesXx_NEWLINE_xXCurrently treated for hyperthyroidismXx_NEWLINE_xXPatient is being evaluated or receiving treatment by the pediatric oncology division at the University of KentuckyXx_NEWLINE_xXCurrently on dialysisXx_NEWLINE_xXCurrently taking imperative medications with significant drug-drug interaction with ciprofloxacinXx_NEWLINE_xXPresence of synchronous malignancy for which the patient is currently receiving active treatmentXx_NEWLINE_xXPatients currently taking other sedative hypnotic medicationsXx_NEWLINE_xXReceiving induction treatment while hospitalizedXx_NEWLINE_xXPatient receiving therapeutic anticoagulationXx_NEWLINE_xXCurrently in hospice careXx_NEWLINE_xXNo limitations on prior therapy for eligibility; eligible patients must be receiving their first allogeneic BMTXx_NEWLINE_xXPatients receiving care from these oncologists who are willing to complete an anonymous surveyXx_NEWLINE_xXPatients receiving care from these oncologists who are willing to be audio recordedXx_NEWLINE_xXCurrently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)Xx_NEWLINE_xXPatients currently receiving active therapy for any cancer, including CRC or NSCLCXx_NEWLINE_xXPATIENTS:Xx_NEWLINE_xXSubjects receiving pre-transplant conditioning/GVHD prophylaxis regimens other than those defined, herein.Xx_NEWLINE_xXCriteria 4, Participant is currently receiving or has received liver metastatic-directed therapy ( eg: radiation, ablation, embolization) less than 4 wks prior to enrollment or hepatic surgeryXx_NEWLINE_xXAnti-platelet agents: if currently receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory or anti-platelet agents, not eligibleXx_NEWLINE_xXPatient currently receiving or had prior treatment for the currently diagnosed breast cancer.Xx_NEWLINE_xXIpilimumab-treated patients must be receiving treatment for the indication(s)\n             approved in their country of residence or where they are receiving treatmentXx_NEWLINE_xXPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug. (Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a list of agents that prolong the QT interval)Xx_NEWLINE_xXThe participant is receiving therapy with immunosuppressive agents.Xx_NEWLINE_xXThe participant is receiving therapy with immunosuppressive agents.Xx_NEWLINE_xXCurrently taking anticoagulant medications or clopidogrelXx_NEWLINE_xXPatients receivingXx_NEWLINE_xXAre currently receiving other medications or radiation intended for the treatment of their malignancyXx_NEWLINE_xXCurrently taking a concomitant medicationXx_NEWLINE_xXOther non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-upXx_NEWLINE_xXPatients who are receiving any other investigational agents; a minimum of 4 weeks wash-out period is required for eligibility; please contact principal investigator, Dr. Swati Kulkarni for further clarificationXx_NEWLINE_xXPatients who are currently receiving another investigational therapy are excludedXx_NEWLINE_xX